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Introduction and outline of the thesis 
Chapter 1   
Introduction 
Squamous cell carcinoma accounts for more than 95% of penile malignant neoplasms.1 
The pattern of dissemination is predominantly lymphogenic to the inguinal nodes.2 
Treatment of patients with penile carcinoma and proven inguinal metastases is 
straightforward and consists of treatment of the primary lesion and regional lymph node 
dissection.3 Treatment of individuals with impalpable nodes, however, has been subject of 
debate for many years. Approximately 20% of these patients harbor clinically occult 
inguinal lymph node metastases.4 Various approaches to detect these metastases have 
been evaluated. Primary tumor characteristics are rather unreliable in predicting occult 
metastases and the same can be said for imaging modalities.5,6 A wait and see policy 
carries the risk that metastases will be detected at a more advanced stage of disease, which 
may have a negative impact on survival.7,8 Therefore, elective inguinal lymph node 
dissection is generally performed. This approach leads to overtreatment in the majority of 
patients as a consequence of the low incidence of occult lymph node metastases. 
Moreover, inguinal lymph node dissection is associated with major morbidity.9 The idea is 
to accurately detect the patient with occult lymph node metastasis who is in need for a 
lymph node dissection.  
In 1977, Ramon Cabañas labeled the node close to the superficial epigastric vein as the 
node that receives direct lymphatic drainage from the primary penile tumor.10 This 
supposition was based on lymphangiographic studies performed via the dorsal penile 
lymphatics. Cabañas named this node the “sentinel lymph node” and assumed that this 
node was always in this particular location. It was postulated that the sentinel lymph node 
was the first node to be involved in case of regional metastases. Cabañas revived the 
concept of sequential lymphatic dissemination initially coined by William S. Halsted 
(1852–1922).11 The sentinel node was considered as the guardian of the lymphatic basin, 
obviating a lymph node dissection if it proved to be free of tumor. Identification of this 
node as advocated by Cabañas was founded on static anatomical landmarks, without 
regard for individual variation in lymphatic drainage patterns. This static approach did not 
gain widespread acceptance, particularly due to the low sensitivity. In 1992, Donald L. 
Morton and Alistair J. Cochran proposed the concept of lymphatic mapping with sentinel 
lymph node biopsy for melanoma.12 They suggested that the node receiving direct 
drainage from a melanoma could be any one node in a particular lymph nodal basin. 
Morton and Cochran used blue dye to visualize the lymphatic duct and followed it to the 
first draining node, i.e. the sentinel node. In 1993, preoperative lymphoscintigraphy and a 
gamma probe were added for better identification of the sentinel nodes. In contrast to the 
static approach of Cabañas, this dynamic approach of sentinel node biopsy, has evolved 
into an important staging tool in breast cancer and melanoma. In 1994, dynamic sentinel 
node biopsy for penile carcinoma was introduced at The Netherlands Cancer Institute-
Antoni van Leeuwenhoek hospital. The initial results were featured in earlier 
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publications.13,14 This thesis deals with more mature data regarding several aspects of this 
novel procedure.  
 
Chapter 2 of this thesis provides background information about penile carcinoma with 
the focus on the management of patients with clinically disease-free regional lymph 
nodes. Chapter 3 addresses the prognostic value of histopathologic primary tumor 
characteristics for occult metastases and the indication for dynamic sentinel node biopsy. 
The most important argument for dynamic sentinel node biopsy is a survival benefit for 
patients in whom occult lymph node metastases are removed at an early stage compared to 
a wait and see policy. In chapter 4 this issue is investigated. Dynamic sentinel node 
biopsy was mainly introduced to prevent the morbidity from elective dissection, but how 
much and which morbidity is associated with the dynamic sentinel node procedure itself? 
Chapter 5 deals with this question. Chapter 6 addresses the observation that 
lymphoscintigraphy can identify lymph nodes outside the usual nodal basins, which can 
improve staging. The success of dynamic sentinel node biopsy depends on a low false-
negative rate. In chapter 7, our false-negative cases are analyzed to gain insight in what 
went wrong and to improve the sensitivity of the procedure. A varying lymphatic drainage 
pattern could be one of the causes of these false-negative sentinel node procedures. To 
better understand possible technical failures, we evaluated the reproducibility of 
lymphoscintigraphy for lymphatic mapping in chapter 8. In an attempt to prevent false-
negative procedures and to improve preoperative staging, ultrasonography was added to 
our dynamic sentinel node biopsy protocol. The value of this approach is assessed in 
chapter 9. In chapter 10, the incidence and causes of non-visualization of sentinel lymph 
nodes on preoperative lymphoscintigrams are analyzed as well as the implications for 
further management. Overall results of ten years dynamic sentinel node biopsy experience 
are evaluated in chapter 11. In chapter 12, the sentinel node-positive cases are analyzed 
for factors that may determine the likelihood of involvement of additional (non-sentinel) 
nodes. The thesis concludes with future prospects regarding detection of occult lymph 
node metastases in patients with penile carcinoma and a summary of the presented data 
(chapter 13 and chapter 14).   
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Introduction 
Squamous cell carcinoma (SCC) is the most common tumor of the penis. The natural 
history and its proclivity to spread via regional lymphatics has well been defined. 
Treatment of individuals with proven inguinal metastases consists of treatment of the 
primary lesion and regional lymph node dissection. Treatment of patients with 
unsuspicious inguinal regions has been controversial for many years. Routine elective 
inguinal lymph node dissection leads to overtreatment in the majority of patients as a 
consequence of the low incidence of occult lymph node metastases. On the other hand, a 
wait and see policy harbors the risk of patients presenting with metastasis at a stage when 
cure is no longer possible. During the last two decades, the management of penile 
carcinoma patients with impalpable regional lymph nodes has improved due to better 
knowledge of risks for metastases, the introduction of modified lymphadenectomy, and 
dynamic sentinel node biopsy. We performed a review of the literature regarding penile 
SCC including its most basic clinical aspects. The focus of this review will be on the 
management of clinically negative regional lymph nodes in patients with penile SCC.  
 
Epidemiology 
Penile carcinoma is an uncommon malignancy in the USA and Europe and accounts for 
less than 1% of adult male cancers in these regions.1,2 Higher incidence rates are seen in 
developing countries, and the disease can constitute up to 10% of malignant disease in 
men in some African, Asian, and South American countries.3-5 Penile carcinoma is 
typically a disease of middle-aged to older men, most commonly affecting those between 
50 and 70 years of age, but the tumor is not unusual in younger men.  
 
Etiology 
Penile carcinoma is primarily seen in uncircumcised men. Phimosis is present in more 
than half the of patients.6 Chronic infection and tobacco are risk factors.6,7 Penile 
carcinoma is associated with high-risk human papilloma virus (HPV), a sexually 
transmittable virus, which is present in approximately 30% of the tumors.8
 
Clinical presentation, natural course, diagnosis and staging 
Up to 90% of penile cancers arise at the glans and prepuce and only a minority at the 
shaft. Clinical presentation of penile carcinoma ranges from a region of induration to an 
ulcer or a warty tumor. Neglect will eventually result in a large tumor involving the 
corpora. Penile carcinoma has a strong tendency for lymphatic spread, with hematogenic 
dissemination only in cases with advanced nodal metastasis. Without treatment, most 
patients will develop metastases and usually die within two years after diagnosis of the 
primary lesion. In general, patients die because of loco-regional progression or from 
distant metastases.9,10 The inguinal lymph nodes are the first site of metastasis followed by 
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the pelvic nodes and sometimes the retroperitoneal nodes. Rarely involved are liver, lungs 
and bones.11 The accuracy of palpation is not sufficient to select patients in whom inguinal 
lymphadenectomy is necessary. Palpable inguinal lymphadenopathy is present at 
diagnosis in 30-60% of the patients.12 In about half of these patients this is caused by 
metastatic invasion and in the other half by inflammatory reactions.13 The easiest way to 
confirm lymph node metastases in patients with palpable nodes is by fine-needle 
aspiration cytology. Obviously, the result is only reliable if positive, false-negative rates 
are reported up to 29%.14 If negative, another fine-needle aspiration is recommended with 
a brief delay. If negative again and in the presence of clinical suspicion, an excisional 
biopsy should follow.15 Occult nodal metastasis is present in approximately 20% of 
patients presenting with impalpable nodes.13 The most commonly used staging system in 
penile carcinoma is the 1987 TNM classification (Table 1).16
 
Table 1 
1987 TNM classification.16
T Primary tumor 
0 No evidence of primary tumor 
is Carcinoma in situ 
a Noninvasive verrucous carcinoma 
1 Tumor invades subepithelial connective tissue 
2 Tumor invades corpus spongiosum or cavernosum 
3 Tumor invades urethra or prostate 
4 Tumor invades other adjacent structures  
  
N Regional lymph nodes 
0 No evidence of regional lymph node metastasis 
1 Metastasis in a single superficial inguinal lymph node 
2 Metastasis in multiple or bilateral superficial inguinal lymph nodes 
3 Metastasis in deep inguinal or pelvic lymph node(s), unilateral or bilateral 
  
M Distant metastases 
M0 No evidence of distant metastasis 
M1 Distant metastasis 
 
Primary tumor treatment 
Small tumors limited to the foreskin can be treated by circumcision with a clear tumor-
free margin. This procedure may be associated with recurrence rates as high as 32% 
especially with tumors in the proximal foreskin illustrating the need for careful follow-up 
after circumcision alone.17 Laser ablation using a neodymium:yttrium-aluminum garnet 
(Nd:YAG) or carbon dioxide (CO2) laser has been used in selected patients with small 
superficial penile cancers (Tis, Ta, and T1) as an alternative for partial amputation. 
Windahl evaluated the efficacy and morbidity of laser compared to conventional treatment 
in patients with superficial penile SCC. The cosmetic and functional outcome of laser 
treatment was excellent and the associated morbidity rate was low compared to partial 
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amputation. Recurrence rates after laser treatment are comparable to those after partial 
amputation.18 We reported on 51 patients using penis-conserving treatment with an 
Nd:YAG laser. Satisfactory cosmetic and functional results were achieved without 
compromising oncological principles.19  
Radiation therapy has yielded local control rates similar to surgical resection in small 
tumors, but more advanced penile cancer is fraught with local recurrences.20-22 Poorly 
differentiated carcinomas or more deeply infiltrative tumors involving the cavernous 
bodies and the distal shaft are best managed by partial penectomy excising 0.5 to 1 cm of 
normal tissue proximal to the margin of the tumor. This should leave a stump of penis to 
allow directable micturition in a standing posture, with some coital function as well. Total 
penectomy with perineal urethrostomy should be performed for bulky T3 or T4 tumors 
involving the base of the penis.  
 
Lymphatic drainage of the penis 
The regional lymph nodes of the penis are located in the groin. Various authors have 
described the anatomy of these nodes.23-25 Traditionally, the inguinal nodes are divided 
into two groups, superficial and deep. The superficial nodes are located beneath the 
Scarpa’s fascia and above the facia lata covering the muscles of the thigh. Eight to 25 
nodes are present. The deep inguinal nodes are situated around the fossa ovalis, the 
opening in the fascia lata where the saphenous vein drains into the femoral vein. Three to 
five nodes are present there. These nodes form the link to the second-line regional nodes, 
i.e. the pelvic nodes. The deep inguinal nodes receive their afferents from the superficial 
ones and directly from the deeper structures of the penis. From a clinical perspective this 
anatomical distinction is useless, as the superficial nodes cannot be distinguished from the 
deep nodes by physical examination. The most constant and usually largest inguinal node 
is found medial to the femoral vein and just underneath the inguinal ligament, the so 
called node of Cloquet. It is customary to divide the inguinal region into four sections by 
drawing a horizontal and vertical line through the point where the saphenous vein drains 
into the femoral vein. The nodes that are involved primarily in penile SCC are mostly 
located in the craniomedial segment, although there is individual variation. The penis 
drains to both sides in most of the patients as is shown by lymphoscintigraphy studies.26 
The pelvic nodes consist of nodes around the iliac vessels and in the obturator fossa. 
Between twelve and twenty pelvic nodes can be found. Inguinal lymphadenectomy 
consists of removal of all regional nodes in the groin and pelvic lymphadenectomy 
comprises removal of all pelvic nodes. The simultaneous removal of these first- and 
second-line nodes is traditionally called ilio-inguinal lymph node dissection. 
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Lymphadenectomy and identification of occult lymph node metastases 
Lymphadenectomy is curative in approximately 80% of the patients who present with one 
or two invaded lymph nodes. Even in patients with pelvic node involvement, cure by 
surgery alone can still be obtained.27-29 The extent and timing of lymphadenectomy have 
been discussed at length. A scientifically sound answer on these issues can be given only 
after prospective randomized trials, but the rarity of penile SCC precludes this type of 
clinical endeavor. The answers to date can only be obtained from large single-institution 
experience.  
 
Extent of lymphadenectomy 
Patients with confirmed metastasis must undergo lymphadenectomy, but how extensive 
the surgery should be is debatable. In general, 20-30% of patients with positive inguinal 
lymph nodes have involved pelvic nodes as well.27,30,31 The likelihood of pelvic node 
involvement is related to the number of positive nodes in the inguinal specimen.32 Patients 
with one positive inguinal node and no involvement of the highest lymph node in the 
dissection specimen have a very low probability of pelvic involvement.27 Additional 
unilateral pelvic node dissection of the affected site is recommended in all other patients 
with inguinal node involvement. The likelihood of bilateral involvement is also related to 
the number of involved nodes in the resected specimen. With two or more metastases, the 
probability of occult contralateral involvement is approximately 30% and warrants early 
contralateral inguinal lymph node dissection.27,31 
 
Timing of lymphadenectomy 
The timing of lymphadenectomy in penile SCC patients with no clinical signs of metastatic 
disease has been controversial for many years. The critical issue is the unreliability of clinical 
methods to detect occult metastases. Controversy exists between proponents of elective 
lymphadenectomy (defined as being carried out in a patient with non-palpable regional lymph 
nodes) and delayed lymphadenectomy (defined as being carried out at first sign of palpable 
lymph node involvement).17,27,33,34 Lymphadenectomy is associated with substantial morbidity 
(24–87%) such as postoperative wound infection (3–70%), skin necrosis (8–60%), seroma (9–
87%) and lymph edema (27–100%). It carries a mortality of up to 3%.5,32,35,36 A wait and see 
policy avoids overtreatment, but this approach carries the risk that metastases will be detected 
at a more advanced stage which may have a negative impact on survival. Early 
lymphadenectomy is unnecessary in up to 80% of the patients because of the low incidence of 
occult lymph node metastases.13,27 As a result of this dilemma much clinical research has 
focused on finding primary tumor prognosticators to identify patients at a high risk of occult 
metastasis. In addition, modified lymphadenectomy and sentinel node biopsy to assess the 
regional impalpable lymph nodes have been introduced.  
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Primary tumor prognosticators for occult metastasis  
The depth of invasion (T-stage) and the grade (G) and of the primary tumor are 
considered to be the most important indicators for lymphatic spread. Grading for SCC 
(well differentiated (G 1), intermediate differentiated (G 2) and poorly differentiated (G 
3)) is based on the work of Broders.37 Several series showed a relation between G3 and 
the presence of lymph node metastases. Also, deeply infiltrating tumors (>T1) have a high 
propensity for nodal spread. Low grade tumors (G1-2) and superficially tumors (Tis-1) 
have a low tendency to metastasize.38-42 By combining these factors, risk profiles for 
lymph node metastases have been identified. Patients with a superficially low grade tumor 
(Tis-1, G 1-2) have a low change of harboring occult lymph node metastasis.39 It has been 
well established that for these patients a careful wait and see policy is justified.39,43,44 In 
deeper invasive and high grade tumors (T1G3 and >T1G1-3) the change of occult nodal 
metastasis is higher and many authors recommend elective lymphadenectomy for these 
patients.38,39,44,45
However, the reliability of this approach is questionable and many unnecessary node 
dissections are still undertaken even in the high risk group. In more than 60% of cases no 
lymph metastases will be found in the resection specimen.15 There is thus ample room for 
improvement. Apart from the classic histopathological parameters, some molecular 
biological parameters have been evaluated for their possible diagnostic value for 
prediction of lymph node metastases.46-48 In general, results of these studies are 
disappointing. The recently developed micro-array technique might give information 
about tumor characteristics on the basis of analysis of its genome, such as the ability to 
generate nodal metastases.49  
 
Imaging 
Computed tomography, ultrasonography, and magnetic resonance imaging are generally 
considered to have a low sensitivity to identify occult metastases as criteria for malignant 
involvement are usually based on size alone.14,50 The main pitfall is due to occult 
metastatic disease occurring within normal sized nodes. Recently, however, two methods 
have emerged to detect clinically occult metastases. First, high resolution ultrasonography 
in combination with fine needle aspiration cytology. Thanks to high resolution probes, 
ultrasonography is able to depict changes in the cortical and hilar morphology and texture 
of an impalpable lymph node that can reflect the presence of underlying metastasis. Due 
to overlap of sonographic features of benign and suspicious lymph nodes, fine-needle 
aspiration cytology of sonographically suspicious nodes provides a more definitive 
diagnosis than ultrasonography alone. Potential applications have been demonstrated in a 
number of malignancies among which SCC of the vulva, a tumor with biological 
similarities to penile SCC.51 In addition, magnetic resonance lymphangiography has been 
developed. By using a mix of small contrast particles, which are taken up by macrophages 
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in the lymph nodes, foci of metastasis show as filling defect on the images. This 
technique, though still largely experimental, showed promise with high specificity and 
sensitivity in prostate cancer and might identify occult lymph node metastases in penile 
carcinoma as well.51
 
Modified inguinal lymphadenectomy 
A modification of the standard complete inguinal lymphadenectomy has been developed 
by Catalona as another option for patients with penile cancer with clinically negative 
inguinal lymph nodes.53 The length of the skin incision is reduced in this approach, the 
subcutaneous tissue superficial to Scarpa’s fascia is preserved, the dissection is reduced to 
exclude the regions lateral from the femoral artery and caudal from the fossa ovalis, the 
saphenous vein is preserved, and transposition of the sartorius muscle is eliminated. 
Modified inguinal lymphadenectomy is intended as a surgical staging procedure only. 
Metastatic disease is treated by a complete inguinal lymphadenectomy. As expected, the 
rate of complications of the modified procedure is lower than that of complete 
lymphadenectomy.35,54 The downside is that the procedure is unnecessary in most patients, 
as no tumor will be found in the resected specimen, and that the associated morbidity is 
still substantial. Moreover, the reliability of this procedure in detecting metastases in 
penile cancer patients with clinically negative groin nodes has been questioned.55
 
Sentinel node biopsy 
Lymphogenic spread appears to be an orderly sequential process. In 1977, Cabañas 
described sentinel lymph node biopsy in penile cancer patients on the basis of 
lymphangiographic studies.56 He labeled the lymph node close to the superficial epigastric 
vein as the sentinel lymph node, i.e. the first lymph node that receives direct drainage 
from the primary tumor. The removal of this node was recommended to detect occult 
lymphatic spread. The identification of this node was based on static anatomical 
landmarks and individual variation in lymphatic drainage patterns was disregarded. This 
approach did not gain widespread acceptance due to a low sensitivity.57-59 Anatomical 
studies showed that the sentinel lymph node area has up to seven lymph nodes located 
between the superficial epigastric vein and the external pudendal vein. Even by extending 
the area of dissection and removing all lymphatic tissue in the area of the superficial 
epigastric vein, and all the nodes medial to the saphenous vein, the true sentinel node can 
be missed.60 The development of the technique of lymphatic mapping by Morton and 
Cochran at the John Wayne Cancer Institute in the late 1980s was a break-through in 
making the sentinel node concept applicable to various types of malignancies.61 In 1994 
this staging method was introduced at The Netherlands Cancer Institute for penile 
carcinoma. We have performed so called dynamic sentinel node biopsy with the dual 
tracer technique in combination with lymphoscintigraphy and a gamma-ray detection 
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probe in 123 penile carcinoma patients.62 Only groins with a positive sentinel node 
undergo complementary inguinal dissection. The identification rate and sensitivity in our 
series are 98% and 82% respectively. 
 
Inguinal radiation therapy 
There seems to be no role for radiation therapy as primary treatment in patients with 
confirmed lymph node metastases. The five-year survival with radiation therapy as 
primary treatment (25%) is half that of surgery (50%).45,63 Prophylactic radiation therapy 
in clinically node-negative patients is not advised because data of literature indicate no 
reduction of the occurrence of palpable nodes compared with surveillance. In patients 
with two or more nodal metastases, extracapsular growth, and pelvic metastases adjuvant 
radiation therapy may increase local control.15
 
Chemotherapy 
Chemotherapy as part of combination therapy should probably be offered to all patients 
presenting with advanced loco-regional disease. This includes patients with immobile 
inguinal nodes and patients with disease extending into neighboring structures like 
symphysis pubis and perineum. The aim of combination therapy is to render these patients 
amenable to surgical therapy. Combination chemotherapy appears to provide responses in 
most the patients with inoperable metastatic disease. The tumor and metastases are 
rendered resectable in half of them with a durable disease-free survival in 15-30%. These 
data are based on two combination chemotherapy regimens of cisplatin and 5-fluorouracil 
and that of vincristine, bleomycin and methothrexate.64-67
Experience with SCC in the head and neck, anus, and cervix has shown promising results 
with concomitant radiation therapy, but hardly any experience has been gathered in SCC 
of the penis.68-70  
 
Survival and follow-up 
In general, half of the patients presenting with lymph node metastases survive more than 
five years after lymph node dissection. Lymphadenectomy in patients one or two positive 
lymph nodes results in a five-year survival of approximately 80%, compared with 17-54% 
when more than two lymph nodes are involved. Survival data from recent series are 
shown in Table 2. A careful follow-up schedule is important for both penile and regional 
recurrences.  
 
20
                                                                                         Management of penile carcinoma 
Table 2 
Five-year survival rates by clinical and pathological N-stage. 
 cN0 cN+ cN1 cN2 cN3 pN0 pN+ pN1 pN2 pN3 
           
Villavicencio71   71 33       
Brkovic29      90  80  17 
Horenblas27 93 50 57 50 17 100  79 17  
Kamat72 75  40 39       
Kulkarni73 81 52    91     
Lopes28       40   54 
Ornellas74      87 29    
Srinivas31      85 32    
 
Conclusion 
Penile SCC poses many diagnostic, staging, and treatment challenges. Laser ablation of 
the primary tumor has a prominent role in patients with a superficial tumor as a penis-
conserving approach. Patients with deeper infiltrating tumors, should undergo (partial) 
penile amputation. For patients presenting with palpable and proven metastatic nodes 
complete (ilio-) inguinal lymphadenectomy should be performed. For patients who 
present with impalpable nodes, the reliability of primary tumor characteristics are of some 
value to predict occult lymph node metastases. Because of the low incidence of occult 
metastases, a wait and see policy is recommended for patients with low-risk primary 
tumors (Tis-1G1-2). Patients with a high risk tumor(T1G3 and T2-4G1-3)  have a higher 
change of occult metastases. For these patients elective modified inguinal 
lymphadenectomy has been advocated in order to reduce the morbidity that would be 
inflicted when elective standard inguinal lymphadentomy would be performed. The 
recently introduced method of sentinel node biopsy offers the opportunity of optimal 
staging in combination with minimally invasive surgery. Non invasive staging with high 
resolution ultrasonography in combination with fine needle aspiration cytology is another 
promising approach. Magnetic resonance lymphangiography is fascinating but still largely 
experimental. Maybe gene-expression profiling will identify a subgroup of patients at high 
risk for occult nodal metastases in the near future. Future perspectives in penile cancer 
comprises continuing research to reduce mutilation without jeopardizing clinical outcome.  
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Introduction 
Patients with penile carcinoma and impalpable inguinal lymph nodes pose a diagnostic 
dilemma. Only a minority of these patients harbor occult metastases in these nodes.1 There 
is a clinical need to find these metastases at the earliest possible stage because survival is 
related to presence and extent of nodal involvement.2 Various approaches to detect occult 
nodal spread have been used and there is still much debate regarding what has to be 
considered the best management. The most invasive approach is elective bilateral inguinal 
lymph node dissection, and the least invasive a “wait and see” policy. An important 
disadvantage of elective dissection is its redundancy and its accompanying morbidity if 
the regional lymph basin is not tumor affected, which is the case in the majority of the 
patients.3 The disadvantage of a wait and see approach is a possibly poorer prognosis at 
the time that malignant lymph nodes become palpable during follow-up.4  
As a result of this dilemma much clinical research has focused on finding primary tumor 
prognosticators to identify patients at high risk for occult lymph node metastasis. Over the 
last 20 years in this regard several primary tumor characteristics have been found to be 
associated with the regional lymph node status such as stage, differentiation grade and 
vascular invasion.5-8 Based on these studies recommendations have been made for staging 
clinically node negative penile carcinoma patients. Only two studies focused solely on 
clinically node negative penile carcinoma.9,10 We analyzed a variety of clinicopathological 
characteristics of penile carcinoma patients, who initially presented with clinically node 
negative groins at our institute to determine their value as predictors of the status of the 
regional nodes. 
 
Patients and Methods 
Patients 
A total of 341 patients with penile carcinoma, treated at The Netherlands Cancer Institute 
between 1956 and 2001 were selected from our tumor registry. Twenty-one patients with 
pathological diagnosis of penile carcinoma in situ were excluded. Seventy-three patients 
were excluded because they initially presented with clinically node positive groins. 
Another nineteen patients were excluded because they had received neo-adjuvant 
chemotherapy or radiotherapy as primary tumor treatment. Finally, three patients were 
excluded because of insufficient data.  
 
Treatment of the primary tumor and the lymph nodes 
Primary tumor treatment consisted of (partial) amputation or local excision in the 
remaining 225 cases. Occult metastases were detected during follow-up in the course of a 
wait and see policy, by elective inguinal lymphadenectomy or by dynamic sentinel node 
biopsy. Until 1988, clinically node-negative patients were usually managed by 
surveillance with clinical assessment of the inguinal regions by physical examinations 
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every two to three months. Patients with clinically node-positive lymph nodes underwent 
lymphadenectomy. This was generally preceded by fine-needle aspiration cytology 
(FNAC). From 1988-1994, immediate lymphadenectomy was performed in patients 
considered to be at high risk for microscopic metastasis (T2-3 poorly differentiated 
primary tumors). Since 1994 dynamic sentinel node biopsy was used for staging patients 
with clinically node-negative T2-T3 penile carcinoma. Only patients with a tumor-
positive sentinel node underwent complementary inguinal lymphadenectomy. Additional 
ipsilateral pelvic (external iliac and obturator) lymph node dissection was performed if 
two or more inguinal lymph nodes were involved, or in the presence of extracapsular 
disease. 
 
Statistical analysis and follow-up 
The Kaplan-Meier method was used to determine the chance for occult metastases 
stratified by various primary tumor characteristics. Time to recurrence was calculated 
from date of diagnoses. The cut-off point was determined at five years. In this way we 
were able to assess in our study group as reliable as possible the likelihood of the presence 
or absence of occult lymph node metastasis, as it is well known that if regional recurrence 
occurs in penile carcinoma, it does so typically within three years after primary tumor 
treatment. Cox regression analysis was used to identify independent factors predicting 
occult metastasis. Six variables were included in this model: stage (<T1 or ≥ T1 ), grade ( 
I or ≥II ), tumor diameter (< 2 cm or ≥ 2 cm), vascular invasion (absent or present) and 
penile recurrence (yes or no).  In case of a penile recurrence the primary tumor 
characteristics only were analyzed for their association with occult metastases. The 
assumption made in this study was that in case of recurrent penile carcinoma occult 
metastases were already present at the time of diagnosis of the primary tumor. Two 
patients had a penile recurrence five and ten years after diagnosis of the primary tumor. 
These tumors were considered as second primaries and only the first primary tumor was 
studied in these patients. Analyses were performed with the Statistical Package for the 
Social Sciences software (SPSS, Chicago, Illinois, USA). In general, patients were 
followed regularly at our institute with intervals of two months during the first two years 
after primary tumor treatment, three months in the third year and every six months 
thereafter.  
 
Pathological evaluation 
One pathologist (M.P.W.G.) reviewed all available specimens of the 225 patients without 
knowledge of clinical outcome. Primary tumors were staged according to the 2002 TNM 
system of the International Union Against Cancer as pT1: tumor invades subepithelial 
connective tissue, pT2: tumor invades corpus cavernosum or corpus spongiosum or pT3: 
tumor invades urethra. Tumors were graded according to Broders as G1: well 
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differentiated, G2: moderately differentiated, or G3: poorly differentiated. Vascular 
invasion was defined as tumor cells within endothelium lined spaces. Tumor diameter was 
measured between the largest distance between two opposite tumor borders. As tumor 
thickness the largest distance between the top of the tumor and the deepest tumor cell was 
taken. Infiltration depth was measured from the intact basal membrane of the nearby 
normal epithelium to the deepest tumor cell.  
 
Results 
Mean age was 64 years (29-92). Median follow-up was 79 months (range 5-582). Overall, 
in 52 (23%) of 225 patients who presented with bilateral clinically node negative groins, 
lymph node metastases came to light. In one patient occult metastases were detected by 
elective lymph node dissection, in 14 patients by dynamic sentinel node biopsy, and 37 
patients developed palpable metastatic lymph nodes during follow-up. In the latter group 
the median interval between date of diagnoses and clinical diagnosis of inguinal nodal 
metastases was eight months (range 1 to 27). Primary tumor characteristics of the patients 
and the chance for occult metastases are shown in Table 1.  
 
Table 1 
Characteristics of  225 penile carcinoma patients who initially presented with bilateral clinically node 
negative groins and the chance for occult metastases. 
 Number of 
patients 
Chance for occult 
metastases (%) 
p-value (log rank) 
pT-stage (1987)    
     T1 103 14 0.008 
     T2-3 122 33  
Tumor grade    
     G1 100 19 0.07 
     G2-3 125 30  
Tumor diameter (cm)*    
     Less than 2 57 19 0.16 
     2 to 5 161 28  
Tumor thickness (mm)*    
     Less than 5 99 14 0.0005 
     5 or greater  111 35  
Tumor infiltration depth (mm)*    
     Less than 5 135 16 0.0001 
     5 or greater 85 41  
Vascular invasion*    
     Absent 203 23 0.004 
     Present 14 54  
Penile recurrence    
     yes 59 33 0.11 
     no 166 22  
* Information of some patients could not be retrieved  
Stage, tumor thickness, infiltration depth and vascular invasion were the best univariate 
prognostic factors for occult metastases, while there was a trend for tumor grade. In 
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multivariate analysis tumor stage (p=0.02, HR 2.3 95% CI 1.2-4.6), vascular invasion 
(p=0.01, HR 0.34 95% CI 0.15-0.77) and penile recurrence (p=0.02, HR 2.0 95% CI 1.1-
3.6), were independently associated with the risk for occult lymph node metastases. In 
table 2 the chance for occult metastases stratified by tumor stage and tumor grade is given.  
 
Table 2 
Incidence of occult lymph node metastases in 225 patients with penile carcinoma stratified per tumor 
stage and tumor grade. The risk for occult metastases in patients with T3 primaries could not be 
investigated appropriately due to small numbers. Number of patients are provided in brackets. 
 T1 T2 T3 
G1 7 % (59) 39% (37) 0% (4) 
G2 16% (34) 30% (59) 20% (5) 
G3 40% (10) 45% (16) 0% (1) 
 
The chance for occult metastases for these patients varies between 7% (T1G1) and 45% 
(T2G3). The number of patients with T3 primaries was too small for reliable analysis 
Fifty-nine patients developed a penile recurrence. In twelve of these patients lymph node 
metastases were detected after the penile recurrence. Four patients out of this group had 
recurrences with a higher stage and grade, four patients had recurrences with identical 
stage and grade and two patients had recurrences with a lower stage and grade compared 
to their primary tumor. In two patient histology of the recurrence could not be assessed 
due to irradiation treatment that was given. 
 
Discussion 
In this study stage, tumor thickness, infiltration depth and vascular invasion were the best 
univariate prognostic factors for occult metastases while there was a trend for grade. In 
multivariate analysis stage, vascular invasion, and penile recurrence proved to be 
independent prognostic factors.   
Except for penile recurrence, more or less similar findings have been reported in studies in 
which no distinction was made between clinically node negative and clinically node 
positive patients. In most of these studies stage and grade emerged as the strongest 
primary tumor prognosticators for lymph node metastasis and therefore these two 
characteristics are widely used in staging penile carcinoma and have been implemented in 
the TNM system. 8,11-14    
The selection of only clinically node negative patients might be an explanation for the 
relatively weak association between occult lymph node metastases and grade in this study. 
Patients with high grade tumors perhaps present more often with clinically node positive 
disease.  
To our knowledge, only two studies exist which focused on the predictive value of 
primary tumor characteristics in clinically node negative patients.15,16 In the first study by 
McDougal, 51 clinically node negative patients were analyzed and a staging system based 
29
Chapter 3                           
on stage and grade was proposed. It was stated that by using this system the percentage of 
patients with impalpable nodes that would undergo unnecessary lymphadenectomies 
would decrease to 20%. However, if we had used this staging system to decide whether or 
not to perform a lymphadenectomy, 65% of our patients would have undergone 
unnecessary dissection. Solsona et al. assessed 37 clinically node negative patients and 
defined three risk groups for nodal metastases. In the high risk group only 17% of the 
patients underwent unnecessary lymphadenectomy. However, if we had used this strategy 
almost 70% unnecessary dissections would have been performed in this group (Table 3).  
 
Table 3 
Staging systems based on stage and grade of primary penile carcinoma as proposed by  McDougal and 
Solsona et al. compared to data from the present study. 
 McDougal  
n=51 
 (%occult 
metastases) 
Present 
study 
n=225 
(%occult 
metastases) 
 Solsona et 
al. 
n=37 
 (%occult 
metastases) 
Present study
n=225 
(%occult 
metastases) 
Stage 1 
(Tis) 
0 0*  Low risk 
(Tis, T1G1) 
 
 0 7* 
Stage 2A  
(T1G1-2) 
0 11 Intermediate risk 
 (T1G2-3, T2G1) 
33 30 
Stage 2B  
(T1G3, T2G1-3, 
T3G1-3) 
78 35 High risk  
(T2G2-3, T3G1-3) 
83 32 
* Patients with Tis were not included in this study 
 
Thus, based on our study the value of combining stage and grade in determining risk 
groups as proposed by McDougal and Solsona et al. seem to be too optimistic. 
Remarkably is the high incidence of occult lymph node metastases in the high risk groups 
of McDougal and Solsona et al. Also the overall incidence of occult lymph node 
metastases in their series was higher than in ours, with 41% in the study of McDougal, 
38% in the study of Solsona et al. and 23% in our study. Perhaps that small numbers and 
selection bias can be hold responsible for these differences. 
Our study shows that patients who developed a penile recurrence are more likely to harbor 
occult metastases than patients who did not. An explanation for this finding might be that 
our assumption (i.e. that in case of recurrent penile carcinoma occult metastases were 
already present at the time of diagnosis of the primary tumor) may be queried. It can be 
hypothesized that in the ten patients in whom lymph node metastases were detected after 
the penile recurrence, occult metastases were not the result of the primary tumor, but of 
the recurrent penile carcinoma instead. This hypothesis is also supported by the fact that 
in most of these patients penile recurrences had a higher stage and grade compared to their 
primary tumors.  
30
                                                               Prognostic tumor characteristics for occult metastases  
  
Our data show that in T1-2G1-3 penile carcinoma patients the risk for occult metastases 
varies between 7 and 45% (Table 2). The risk for occult metastases in patients with T3 
primaries could not be investigated properly in our study because of small numbers. In 
addition, the risk for occult metastases in patients with a T1G1 primary in this study 
probably is too high assessed as a result of  the debatable assumption regarding  penile 
recurrences. Only one patient with a T1G1 developed lymph node metastases in the 
absence of a penile recurrence. Therefore, a careful wait and see policy seems justified 
only in patients with T1G1 primaries because of the relatively low chance for occult 
metastases. For the other T1 and T2 patients, who accounted for almost 70% of the 
clinically node negative patients in our series, the risk for occult metastases varies 
between 16 and 45%. Immediate detection and treatment of lymphatic spread in these 
patients seems warranted.  
More recently vascular invasion has been advocated as a predictive factor for lymph node 
involvement. Its value, however, seems limited due to the varying frequencies in which 
this factor is reported. In our study vascular invasion was found in only 6% of the patients, 
while other investigators report up to 44% presence of vascular invasion.17-19 Maybe that 
selection bias and more thorough searching for vascular invasion explains the higher 
detection rates.  
It is obvious that more reliable prognostic factors are needed to assist in the selection of 
patients at high risk of harboring occult metastases. Some molecular biological parameters 
have been evaluated for their diagnostic value for prediction of lymph node metastases.20-
22 In general, results of these studies are disappointing. Maybe, the recently developed 
DNA microarray gene-expression profiling fills in the information gap. Experience with 
this novel technique in head and neck squamous cell carcinoma is promising.23  
Possibly in the near future also in penile squamous cell carcinoma occult metastases will 
be identified by means of DNA microarray gene-expression profiling. But until that time 
primary tumor characteristics have to be considered rather unreliable in detecting occult 
metastases.  
During last years several publications have shown the survival benefit of immediate 
resection of occult lymph node metastases.24-26 In order to identify lymph node metastases 
at the earliest possible moment, at our institute we stage clinically node negative penile 
carcinoma patients by dynamic sentinel node biopsy. This new procedure provides a 
means of assessing lymph node status through a minimally invasive procedure. Only one 
to a few nodes at most, considered pivotal in the spread of the disease are removed with 
the aid of preoperative lymphoscintigraphy, intra-operative gamma ray detection, and a 
vital dye. Dynamic sentinel node biopsy is an attempt to diminish the risk of 
complications without jeopardizing the oncological outcome. Only patients with tumor-
positive sentinel nodes undergo additional complementary inguinal lymph node 
dissection.27
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Until recently only patients with T2-3 tumors were included in our dynamic sentinel node 
biopsy protocol because it was thought that clinically node negative patients with a T1 
tumor, regardless of grade, had a low risk of harboring occult metastases. Based on the 
results of the present study we now have decided to extend the indication for dynamic 
sentinel node biopsy to patients with T1G2 and T1G3 tumors.  
 
Conclusion 
By combining stage and grade of the primary tumor in penile carcinoma patients with 
clinically node negative groins groups can be identified with a chance for nodal spread 
that varies between 7 and 45% for patients with a T1-2 /G1-3 primaries. Only patients 
with a T1G1 primary seem to have low risk of harboring occult lymph node metastases. 
These patients might be good candidates for a surveillance policy. For all other patients 
immediate histological assessment of the regional nodes seems necessary. 
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Introduction 
The timing of lymphadenectomy in penile squamous cell carcinoma  (SCC) patients with 
metastatic regional disease has been discussed for many years. Controversy exists 
between proponents of early lymphadenectomy (defined as being carried out in a patient 
with non-palpable node-negative groins) and delayed lymphadenectomy (defined as being 
carried out at first sign of lymph node involvement in the course of a watchful waiting 
program). Early lymphadenectomy with its associated substantial morbidity is 
unnecessary in most of the patients because of the low incidence of occult lymph node 
metastases. Although a wait and see policy avoids overtreatment, it carries the risk that 
metastases will be detected at a more advanced stage of disease which may have a 
negative impact on survival.1-5  
Several authors sensed survival advantage with early dissection and recommended this 
approach in clinically node negative penile SCC patients.1,5 Other investigators suggested 
a wait and see policy in combination with a meticulous follow-up.2,4 They reserved 
dissection only for those patients who developed palpable nodes during a strict follow-up. 
The rationale behind this approach is the assumed notion that patients who develop 
palpable nodes can be salvaged by lymph node dissection without any negative impact on 
survival compared to early lymphadenectomy. At our institute we have always been 
proponents of this wait and see policy in combination with a strict follow-up.2,6
A problem in comparing early versus delayed lymphadenectomy is that these comparisons 
are often statistically underpowered since only approximately 20% of the T2-3 patients 
with clinically node-negative groins harbor occult regional metastases.7 Thus, the node-
negative patients may dilute the potential effect on survival in the minority of patients 
with regional lymph node metastases. Therefore, we choose an alternative approach and 
focused on the sub-population of patients with proven lymphatic metastases. 
Undoubtedly, this is the only target group that benefits from any type of lymph node 
dissection.  
Until 1994, clinically node-negative patients with SCC of the penis were managed without 
early lymphadenectomy. Instead, they were meticulously followed after primary tumor 
treatment at our institute. This surveillance policy was based on a 100% compliance with 
follow-up and a presumed safety of immediate treatment of clinically demonstrable 
disease. From 1994 on, clinically node negative patients harboring clinically occult lymph 
node metastases as proven by dynamic sentinel node biopsy (DSNB) underwent early 
lymphadenectomy. 
The aim of this study was to compare the clinical outcome of patients undergoing delayed 
lymph node dissection under a strict surveillance program and patients undergoing early 
lymph node dissection after detecting lymph node metastases with DSNB.  
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Methods 
Patients 
The present study includes 40 patients with a T2-3 penile carcinoma initially presenting 
with clinically node-negative groins. All patients developed lymph node metastases 
during follow-up or harbored tumor-positive sentinel nodes. All patients were treated at 
our institute between 1960-2002. Patients with T1 tumors or carcinoma in situ were not 
included because of the assumed low risk of occult metastases. Between 1960-1994, 20 
patients underwent delayed lymph node dissection after cytologically proven metastases 
of enlarged lymph nodes during a wait and see policy. In 20 patients, treated between 
1994-2002, DSNB resulted in early diagnosis and treatment of clinically occult nodal 
disease. In all patients regional lymph node metastases were histologically proven.  
 
Primary tumor treatment 
Primary tumor treatment consisted of (partial) amputation in 38 patients and radiotherapy 
in two. 
 
Dynamic sentinel node biopsy 
The two-day DSNB-protocol has been described in detail previously.8 Briefly, 
lymphoscintigraphy was performed the day before surgery and the location of the sentinel 
node was marked on the skin. A gamma-ray detection probe (Neoprobe®, Johnson & 
Johnson Medical, Hamburg, Germany) and patent blue dye (Blue-Patenté V, Laboratoire-
Guerbet, Aulnay-sous-Bois, France) were used to identify the sentinel node intra-
operatively. Complete inguinal lymphadenectomy was performed when the pathology 
evaluation of the sentinel node revealed metastasis. 
 
Inguinal lymphadenectomy and adjuvant radiotherapy 
Inguinal lymphadenectomy consisted of the removal of all lymphatic tissue between the 
inguinal ligament cranially, the adductor longus muscle medially, the sartorius muscle 
laterally, the crossing point of the sartorius and adductor longus muscles caudally, and the 
pectineus muscle and the superficial femoral artery and vein and dorsally. Additional 
ipsilateral pelvic (external iliac and obturator) lymph node dissection was performed if 
two or  more inguinal lymph node were involved. Patients underwent adjuvant regional 
radiotherapy if histopathological examination showed extracapsular involvement or when 
at least two lymph nodes were invaded by tumor. 
  
Pathology evaluation  
Primary tumors and the specimens from inguinal lymphadenectomy were examined using 
routine histology. Paraffin sections of the sentinel nodes were stained with hematoxylin 
and eosin, and immunohistochemical examination was carried out using pankeratin and 
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CAM 5.2 (Becton Dickinson, San Jose, California, USA). Primary  tumors were staged 
according to the 1978 TNM system of the International Union Against Cancer. Tumors 
were graded as well, moderately or poorly differentiated according to Broders.9 Vascular 
invasion was defined as tumor cells within endothelium lined spaces. Infiltration depth 
was measured from the intact basal membrane of the nearby normal epithelium to the 
deepest tumor cell. All resection specimens were histologically reviewed by one 
pathologist (M.P.W.G.) without knowledge of clinical outcome.  
 
Follow-up 
To avoid a lead-time bias, survival was calculated from time of primary tumor treatment. 
All patients were followed regularly at The Netherlands Cancer Institute with intervals of 
two months during the first two years after diagnosis, with intervals of three months in the 
third year and every six months thereafter. 
 
Statistical analysis 
Mann-Whitney-U test, Chi-square test, and Fisher’s exact test were used for univariate 
comparison. Disease-specific survival plots were made using the Kaplan-Meier method 
and survival rates were analyzed for significance using the log rank test. Cox proportional 
hazards analysis was applied testing stage, grade, infiltration-depth, vascular invasion and 
timing of lymphadenectomy for their independent effect on survival. For disease-specific 
survival, the event was death of penile carcinoma. In the absence of an event, censoring 
took place at the last follow-up or death of another cause than penile carcinoma. 
Individual model covariates were characterized with 95% confidence interval on the 
hazard ratio scale. Significance was determined at p<0.05. Analyses were performed with 
the Statistical Package for the Social Sciences software (SPSS, Chicago, Illinois, USA). 
 
Results 
The median follow-up after the primary diagnosis was 52 months (range 26-112) in 
patients whose metastases were removed early, and 256 months (range 122-522) in 
patients with a delayed lymph node dissection. None of the patients alive had evidence of 
disease at last follow-up. In the delayed dissection group, the median interval between 
treatment of the primary tumor and clinical diagnosis of inguinal nodal metastases was six 
months (range 1-24). No patients were lost to follow-up. The clinical and histological 
characteristics of the two treatment groups are shown in Table 1. Patient and primary 
tumor characteristics were distributed similar among both groups.  
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Table 1 
Patient, primary tumor and lymph node characteristics. 
 Delayed 
resection 
Early 
resection 
 p-value 
Number of patients 20 20  
Mean age (years) 59.9 58.2 0.62 (Mann-Whitney U test) 
No. disease related death 13 3 0.003 (Fischer exact test) 
PRIMARY TUMOR*    
Clinical T-stage    
     T2 17 16 1.0 (Fisher exact test) 
     T3 3 4  
Pathological T-stage    
     T2 16 17 1.0 (Fisher exact test) 
     T3 2 3  
Tumor grade    
     I 8 5 0.27 (Fisher exact test) 
     II 9 11  
     III 1 4  
Infiltration depth    
     5 mm or less 6 7 0.91 (Chi-square test) 
     Greater than 5 mm 12 13  
Vascular invasion    
     absent 16 17 1.0 (Fischer exact test) 
     present 2 3  
LYMPH NODES    
Involvement    
     Unilateral 13 15 0.49 (Chi-square test) 
     Bilateral  7 5  
Extracapsular growth (No. patients) 19 4 < 0.001 (Fisher exact test) 
Mean No. involved nodes/basin (range) 2.1 (1-6) 1.6 (1-5) 0.005 (Mann-Whitney U test) 
* When available (radiotherapy was primary tumor treatment in 2 patients) 
 
A significantly higher number of metastatic lymph nodes with significantly higher percentage 
of extracapsular growth was found in the patients who underwent delayed dissection. As 
shown in Figure 1, the disease-specific survival rate was significantly higher for the patients 
with early diagnosis and treatment of their lymph node metastases.  
 Figure 1  
Disease-specific survival after
primary tumor treatment: early
lymph node dissection (n = 20)
appears to provide a significant
survival benefit over delayed
dissection (n = 20, log rank test p =
0.0017). Numbers of patients at risk
are provided at each point of time. 
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The estimated three-year disease specific survival rates for early and delayed excision 
were 84% and 35% respectively (p=0.0017). In the delayed dissection group, 13 of 20 
patients died of penile cancer. In the early group, this was three of 20. No other 
parameters than early versus late dissection of occult metastases were significant 
univariate predictors of disease-specific survival. If patients with micrometastases 
(defined as a metastases smaller than 2mm) only in their sentinel nodes (n=6) were 
excluded from analysis, the estimated three-year disease specific survival rates for early 
and delayed dissection were 82% and 35% respectively (p=0.0045). Using a Cox 
proportional hazard model, early resection of lymphatic metastases turned out to be the 
only prognostic factor of disease-specific survival (p=0.006, Table 2).  
 
Table 2 
Cox multivariate regression analysis for disease-specific survival. 
Variable p-value Hazard ratio  
(95% confidence interval) 
Clinical T-stage (T2 or T3) 0.57 1.50 (0.37 – 6.20) 
Vascular invasion (absent or present) 0.97 0.98 (0.45 – 2.17) 
Tumor grade (I or II / III) 0.82 1.14 (0.35 – 3.75) 
Invasion depth (≤ 5mm or > 5mm) 0.89 1.09 (0.32 – 3.67) 
Timing of  lymphadenectomy  (early or late) 0.006 0.17 (0.05 - 0.60) 
 
Discussion 
This single institutional study shows a three-year disease specific survival benefit for 
penile cancer patients in whom lymph node metastases were resected at a clinically occult 
stage compared to patients who underwent lymphadenectomy after inguinal nodes 
manifested clinically obvious. After surveillance, several patients presented with 
massively involved regional lymph nodes, despite a rigid follow-up schedule with 100% 
compliance. Prospective randomized clinical trials comparing early and late resection of 
lymph node metastases have never been conducted, most likely because of the rarity of 
the disease.  
Notwithstanding the retrospective nature of this study, a survival benefit of 49% for 
patients treated by removal of clinically occult metastases is remarkable. While a possible 
survival benefit could only be suggested in a previous report, excluding patients without 
lymph node metastases clarifies the present survival differences.10 This survival benefit 
could not be explained by differences in patient or primary tumor characteristics. We 
submit that penile carcinoma is more likely to be curable at an early stage of disease. The 
finding that early lymph node dissection proved to be an independent favorable prognostic 
factor in multivariate analysis for patients harboring lymph node metastases supports this 
theory. Despite the fact that we have always been proponents of a rigid wait and see 
strategy in T2-3 clinically node negative patients we are disappointed by the presumed 
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safety since we were only able to salvage a minority of patients who developed lymph 
node metastases (7 of 20).  
So, waiting for occult metastases to become clinically apparent seems detrimental for 
survival outcome. But how to identify non-palpable metastases? This is a key issue not 
only from the perspective of improving survival but also to avoid the unnecessary 
morbidity from elective lymphadenectomy that would be inflicted upon the majority of 
patients because they do not have lymph node metastases. Literature on lymph node 
dissection in penile cancer reveals up to 80% absence of metastases in the resected 
specimen.7 In our series 23% of the T2-3 patients presenting with clinically node negative 
groins harbored nodal metastases.10   
Much clinical research is, therefore, focused on finding less invasive prognosticators to 
identify patients at a high risk of occult metastasis. Unfortunately, these efforts have not 
been uniformly successful. Grade of differentiation, depth of infiltration, and presence of 
vascular invasion of the primary tumor are predictive factors for nodal metastases.11-13
However, relying solely on these characteristics for the decision to perform regional node 
dissection will lead to unacceptable false-negative and false-positive rates. Therefore, 
nodal tissue analysis is still necessary.  
Modified inguinal lymphadenectomy, for the first time reported by Catalona et al,14 has 
been advocated as an alternative to complete inguinal lymphadenectomy. In this 
procedure, the saphenous vein is spared and thick skin flaps are preserved. A much 
smaller amount of lymphatic tissue is removed compared to standard lymphadenectomy. 
Modified inguinal lymphadenectomy is meant as a surgical staging procedure only. 
Metastatic disease is treated by a complementary inguinal lymphadenectomy. As 
expected, the rate of complications of the modified procedure is lower than that of 
complete lymphadenectomy. The other side of the picture is that the procedure is 
unnecessary in most patients, as no tumor will be found in the resected specimen, and that 
its morbidity is still substantial.15 Moreover, the reliability of this procedure in detecting 
metastases in penile cancer patients has been questioned.16
DSNB is another attempt to diminish the risk of complications without jeopardizing the 
oncological outcome. This novel approach that was introduced at our institute in 1994, 
provides a means of assessing lymph node status through a minimally invasive procedure. 
Only one or two nodes considered pivotal in the spread of the disease are removed with 
the aid of preoperative lymphoscintigraphy, intra-operative gamma ray detection, and a 
vital dye.8 Only patients with tumor-positive sentinel nodes undergo complementary 
inguinal lymphadenectomy. This minimally invasive procedure decreases morbidity by 
preventing unnecessary lymph node dissections and removes tumor-positive nodes at the 
earliest possible moment. One important caveat is the reported false-negative rate of 18%. 
Analysis of the false-negative procedures in our series led to recent technical adaptations, 
that will hopefully increase the sensitivity of the procedure.17 It is our feeling that the 
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benefits of DSNB will eventually outweigh the risk of false-negative findings. The pros 
and cons together with the alternative approach should be discussed with the patient. 
Clinically node negative patients with T2 and T3 tumors, regardless of other 
histopathological features, are candidates for this innovative procedure at our institute. 
Recently, two other techniques have emerged with the potential to identity occult lymph 
node metastases. First magnetic resonance lymphangiography. By using an infusion of 
ultra small particles which are taken up homogeneously by functioning macrophages in 
normal nodes, foci of metastasic disease show as filling defect on subsequent images. This 
technique, though still largely experimental, showed promise with high specificity and 
sensitivity in prostate cancer.18 Another method for detection of occult lymph node 
metastases involves the use of high-resolution ultrasound guided fine-needle cytology. 
Modern ultrasound not only visualizes alteration in size, shape and contour of lymph 
nodes but also depicts changes in the cortical and hilar morphology and texture that can 
reflect the presence of underlying metastasis. Potential applications have been 
demonstrated in a number of malignancies among which SCC of the vulva, a tumor that 
behaves similar to penile SCC.19  
Possible biases that may have influenced our results have to be discussed. . One could 
argue that not all patients with micrometastases will develop macrometastases later on. In 
an attempt to avoid such a bias, we performed a sub-analysis for survival in which patients 
who had nodal micrometastases only were excluded. The differences remained 
statistically significant. Another criticism might be that some patients will develop distant 
metastases prior to the occurrence of palpable lymph node metastases. This is a rare event 
in penile SCC. However, these patients with a poor prognosis, who cannot be 
distinguished at the time of primary tumor excision, worsen the outcome of the early 
dissection group. Also the differences in follow-up between the study groups does not 
seem to influence results, since it is well known that if regional recurrence occurs, it does 
so typically within two years.20 No patient had evidence of disease at last follow-up, with 
a minimum follow-up of 26 months.  
Taken together, conceivable biases of our study design contribute to diminishing of a 
possible survival benefit of early over delayed excision of inguinal lymph node 
metastases. Nevertheless, we observed a highly significant survival benefit in favor of 
early treatment. This benefit may be explained by the fact that the number of lymph node 
metastases and the percentage of extracapsular growth was significant higher in the 
delayed group. These results strongly support the view that lymphadenectomy should be 
performed at the earliest possible moment in patients harboring clinically occult 
metastases. Identifying these patients can be achieved by DSNB. At this moment, only 
this strategy enables to prevent unnecessary lymph node dissection while increasing the 
changes of cure.  
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Conclusion 
Immediate resection of occult lymph node metastases in patients with penile cancer 
improves survival over resection at the time they become palpable. A wait and see policy, 
even in combination with a strict two-monthly follow-up and 100% compliance, seems no 
longer justified for patients with T2-3 tumors and bilateral impalpable inguinal nodes. 
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Introduction 
The most important prognostic factor for survival in patients with penile squamous cell 
carcinoma (SCC) is the tumor-status of the inguinal lymph nodes.1 For that reason, there 
is a clinical need to find lymph node metastases at the earliest possible stage, preferably 
when still impalpable. Clinical methods for detection of lymphatic spread, however, have 
limited potential to identify occult metastases and primary tumor characteristics as 
predictor for nodal disease are rather unreliable. Therefore, inguinal lymphadenectomy 
carried out on a groin without palpable lymph nodes, is generally performed.2 However, 
the associated postoperative complications pose a serious drawback.3 Moreover, this 
procedure is unnecessary in the majority of patients, because only a minority of those who 
present with clinically node-negative groins harbor lymphatic metastases.  
Dynamic sentinel node biopsy (DSNB) facilitates detection of microscopic lymph node 
invasion in clinically node-negative groins. Only one or two nodes considered pivotal in 
the spread of the disease are removed with the aid of preoperative lymphoscintigraphy, 
intra-operative gamma ray detection, and a vital dye.4 Only patients with tumor-positive 
sentinel nodes undergo additional standard inguinal lymphadenectomy. DSNB is an 
attempt to diminish the exposure to the risk of complications without jeopardizing the 
oncological outcome. DSNB for penile cancer was adopted at our institute in 1994 and 
results have been published before.4-6 The morbidity of the procedure has not been 
previously reported. The purpose of the present study was to assess morbidity of DSNB at 
our institute.  
 
Materials and Methods 
From 1994 till June 2003, 114 consecutive patients with clinically node negative penile 
cancer were prospectively enrolled in this study. In addition, 15 patients with an unilateral 
N1 stage based on physical examination, ultrasound, and fine-needle aspiration cytology 
were entered. These patients underwent DSNB for the clinically unaffected site. Thus, 129 
patients with 243 clinically node negative groins were studied. The mean age was 64 
years (range 28-90). Patients were not eligible for DSNB if the tumor was staged as T1 or 
carcinoma in situ (1987 TNM classification for penile SCC) because of the assumed low 
risk of occult metastasis.  
The two-day DSNB protocol has been described in detail previously.4 Briefly, the day 
before surgery for the primary tumor, lymphoscintigraphy is performed for lymphatic 
mapping and marking of the location of the sentinel nodes on the skin. A gamma ray 
detection probe and patent blue dye are used to intra-operatively identify the sentinel 
nodes. Dynamic sentinel node biopsy was followed by local excision of the primary lesion 
or penile amputation during the same session. Only groins with positive sentinel nodes 
underwent standard inguinal lymphadenectomy. This procedure consisted of the removal 
of all lymphatic tissue between the inguinal ligament cranially, the adductor longus 
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muscle medially, the sartorius muscle laterally, the proximal crossing point of the 
sartorius and adductor longus muscles caudally, and the pectineus muscle and the 
superficial femoral vein and artery dorsally. The saphenous vein was usually preserved 
and the sartorius muscle was transposed. Additional ipsilateral pelvic lymph node 
dissection was performed if two or more inguinal lymph nodes were involved. Patients 
were followed regularly at The Netherlands Cancer Institute with intervals of two months 
during the first two years after diagnosis, with intervals of three months in the third year 
and every six months thereafter.  
The morbidity was assessed by analysis of detailed hospital and outpatient clinic records, 
and was divided in early and late complications. Early (postoperative) complications were 
defined as complications occurring within 30 days of surgery. Thereafter, complications 
were classified as late. Lymphedema of limb was graded as mild (swelling on close 
inspection), moderate (readily apparent deviation from normal anatomic contour) or 
severe (gross deviation from normal anatomic contour interfering with activities of daily 
life) according to the Common Toxicity Criteria.7 The complications of DSNB and 
standard inguinal lymphadenectomy followed by a positive DSNB were recorded 
separately. Potential differences between complications of DSNB and complications of 
DSNB followed by standard inguinal lymphadenectomy were analyzed using the Chi-
Square Test or Fischer’s Exact Test. Statistical methods were two-tailed with p<0.05 
considered statistically significant.  
 
Results 
A total of 285 sentinel nodes were harvested in 223 groins. Exploration of the other 20 
basins was not performed because of lymphoscintigraphic non-visualization (19 basins) or 
because of the absence of a radioactive count rate higher than the background count rate 
during surgery (one basin). The sentinel node revealed metastasis in 34 groins of 29 
patients. In these patients 34 standard inguinal lymphadenectomies were performed. 
Seven additional ipsilateral pelvic lymph node dissections were performed in five patients 
because two or more inguinal lymph nodes were involved. Median follow-up was 50 
months (range 5-124). Two patients were lost to follow-up because of emigration after 
five and 16 months respectively. Regional recurrence after excision of  tumor-negative 
sentinel nodes or after nonvisualization occurred in 6 groins. Details of the false-negative 
procedures have been previously published.6  The false-negative rate calculated per groin 
was 15% (6 of 40 groins). This percentage was 17%, when calculated per patient (6 of 35 
patients). Overall, 40 of 243 (16%) clinically node-negative groins contained metastases.  
Early complications after DSNB occurred in 14 out of 189 groins (7%), and after DSNB 
followed by standard inguinal lymphadenectomy in 21 out of 34 groins (62%).  
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Late complications after DSNB were seen in one out of 189 groins (1%), and after DSNB 
plus additional standard inguinal lymphadenectomy in 11 of 34 groins (32%). The 
morbidity per groin taken as the sum of early and late complications after DSNB, and 
DSNB followed by standard inguinal lymphadenectomy is listed in Table 1.  
 DSNB DSNB+SIL 
n=34 
p-value 
n=189 
Groins with complication 14 (7%) 23  (68%) <0.001 
Wound infection 5 (3%) 6 (18%) 0.002 
Wound abscess 3 (2%)* 3 (9%)* 0.047 
Skin edge necrosis 1 (1%) 5 (15%) <0.001 
Wound dehiscence  1 (1%) 4 (12%)* 0.002 
Seroma 4 (2%) 3 (9%) 0.074 
Lymphocele  1 (1%) 4 (12%) 0.002 
 Mild/Moderate lymphedema  2 (1%) 10 (29%) <0.001 
Severe lymphedema 0 (0%) 1 (3%) 0.152  
 Erysipelas 0 (0%) 3 (9%) 0.003 
 Delayed bleeding 1 (1%) 0 (0%) 1.000  
 
 
 
 
*   Need of intervention. All abscesses needed drainage, 1 wound (after 
DSNB+SIL ) needed a skin graft because of dehiscence      
Table  1 
Complications per operated
groin after dynamic sentinel
node biopsy (DSNB), and
DSNB followed by standard
inguinal lymphadenectomy
(DSNB+SIL). Some patients
had more than one
complication per groin. 
The overall complication rate after DSNB (7%) was lower than after standard inguinal 
lymphadenectomy because of tumor-positive sentinel nodes (68%, p< 0.001). 
Average duration of admission after DSNB and treatment of the primary tumor was 5.6 
days (range 3-16), as compared to 16.0 (range 6-38) days after standard inguinal 
dissection because of  tumor-positive sentinel nodes (p<0.001).  
 
Discussion 
Standard inguinal lymphadenectomy in clinically node-negative patients provides 
important prognostic information and removes micrometastases at the earliest possible 
moment. Advocates of dissection will point to the fact that all procedures but a standard 
lymphadenectomy harbor the risk of false-negative findings, thus putting the patient in 
danger of incurable disease. While that statement makes sense, long-term survivors with 
debilitating lymphedema after a tumor-negative lymph node dissection are the living 
evidence that refinement in the surgical approach is needed.  
Much clinical research is focused on finding less invasive prognosticators to identify 
patients at a high risk of occult metastasis. In penile cancer, these efforts have not been 
very successful so far. Stage, grade of differentiation, depth of infiltration, and presence of 
vascular invasion of the primary tumor are predictive factors for nodal metastasis.8-10 
However, relying solely on these characteristics for the decision to perform regional node 
dissection will lead to unacceptable false-negative and false-positive rates. Therefore, 
nodal tissue analysis still is necessary. Surgical oncology research is looking for ways to 
minimize the incidence and nature of complications of surgical staging. Modified inguinal 
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lymphadenectomy, reported for the first time by Catalona et al,11 has been advocated as an 
alternative to standard inguinal lymphadenectomy. In this procedure the saphenous vein is 
spared and thick skin flaps are preserved. A much smaller amount of lymphatic tissue is 
removed compared to standard inguinal lymphadenectomy. Modified inguinal 
lymphadenectomy is meant as a surgical staging procedure only. Metastatic disease is 
treated by an additional standard inguinal lymphadenectomy. As expected, the rate of 
complications of the modified procedure is lower than that of standard inguinal 
lymphadenectomy, as is displayed in Table 2.  
 
Table 2 
Complications of standard inguinal lymphadenectomy (SIL), modified inguinal lymphadenectomy 
(MIL), and dynamic sentinel node biopsy (DSNB). Present series and data of the literature. NA = Not 
available. 
 
 
Period No.  of  
lymphadenectomies 
Skin edge 
necrosis, slough 
Lymphedema  Wound infection,  
abscess  
Seroma, 
lymphocele  
Other 
 
SIL         
Johnson15 1948-1983 101 50% 65% 14% 25% 8% 
Ravi16 1962-1990 405 62% 27% 17% 7% 0% 
Ornellas 17 1972-1987 200 45% 23% 15% 6% 0% 
Bevan-Thomas3 1989-1998 40 13% 21% 18% 15% 7% 
Present series  1994-2003 34 15% 32% 26% 21% 21% 
Total  780 51% 31% 16% 10% 2% 
        
MIL        
Catalona11 NA 6 0% 67% 0% 17% 17% 
Parra18 1988-1994 14 0% 0% 0% 0% 0% 
Lopes12 1993-1995 26 0% 19% 15% 31% 0% 
Colberg19 NA 12 8% 42% 0% 8% 17% 
Bevan-Thomas3 1989-1998 66 5% 14% 9% 12% 9% 
Coblentz20 1995-2001 12 8% 17% 0% 8% 25% 
Total  136 4% 18% 7% 14% 9% 
        
DSNB        
Present series 1994-2003 189 1% 1% 4% 3% 1% 
 
The other side of the picture is that modified inguinal lymphadenectomy as a staging 
procedure is unnecessary in the majority of patients, as no tumor will be found in the 
resected specimen. Moreover, false-negative results have been reported.12  
DSNB provides a means of assessing lymph node status through a minimally invasive 
procedure. Complications of DSNB in penile carcinoma have not been well publicized or 
quantified so far. Morbidity rate of this staging procedure was 7% in the present series 
(Table 1). All complications were minor and resolved without long-term sequelae. To 
decrease morbidity of DSNB even further we introduced two technical additions recently. 
In order to prevent lymphoceles, afferent lymph vessels are ligated and to prevent seroma 
the excision cavity of the sentinel node is meticulously closed. Morbidity figures of 
DSNB in patients with penile SCC are in accordance with those of DSNB in other 
malignancies with reported percentages in melanoma and breast cancer ranging from 5-
10%.13,14 Instead of the unselective removal of lymphatic tissue, DSNB with its low 
morbidity is in theory more attractive than any other surgical staging method.  
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However, the reliability of the procedure has not been established firmly and in this study 
tumor outgrowth in an earlier mapped tumor-negative regional basin occurred in 6 cases. 
After all, an in field recurrence after a negative DSNB is perhaps the greatest 
complication of the procedure. Nevertheless, the sensitivity of the procedure has increased 
over the last years. Most false-negative cases were encountered early on during the study, 
at the beginning of our learning curve, when the technique was not yet well established. 
More recently, important technical adaptations have been introduced after analysis of the 
false-negative cases and will hopefully further increase the sensitivity of the procedure.6 
Ongoing assessment will focus on the question whether the risk of false-negative findings 
is acceptable. Hopefully the benefits of DSNB will outweigh the risk of false-negative 
findings. With the advance of DSNB there may be less room for inguinal 
lymphadenectomies in clinically node-negative patients with penile SCC.  
 
Conclusions 
Morbidity of DSNB in penile SCC is low. However, an in field recurrence after a negative 
DSNB is perhaps the greatest complication of the procedure. 
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Introduction 
It is rare to find a lymph node in the prepubic area. Nodes in this area have been 
demonstrated in a few dated anatomical studies only (Bazy (1902), Decloux (1902) and 
Rouvière (1932)).1-3 Mostly they are considered as aberrant inguinal lymph nodes. During 
the last decades such nodes were never seen on lymphangiographic and 
lymphoscintigraphic studies. Recently, however, we have come across a case of penile 
cancer in which the preoperative lymphoscintigram showed a prepubic sentinel node. 
During surgery the node could be identified and harvested. 
 
Case report 
A 52-year old man presented with a T2 penile carcinoma on his glans and a clinically 
node-negative groin on the right side. Enlarged nodes were palpated in the left groin and 
these were proven to be tumor-positive by fine-needle aspiration cytology. The patient 
was scheduled for penile amputation, unilateral lymph node dissection and sentinel node 
biopsy for the clinically node-negative right basin.  
On the day before surgery, TC-99m-nanocolloid (Nanocoll®, Amersham Cygne, 
Eindhoven, the Netherlands) was intradermally injected around the tumor using a volume 
of 0.4 ml and a radioactivity dose of 58 MBq (1.55 mci), divided into three depots. 
Dynamic anterior lymphoscintigraphy was performed during ten minutes immediately 
after injection. Subsequently, five minute anterior and lateral static images were obtained 
after ten minutes and two hours post-injection. A dual-head gamma camera (ADAC 
Vertex®, Milpitas, California, U.S.A.) was used. Both anterior and lateral images were 
obtained. The early static lymphoscintigraphy image showed a prepubic first draining 
lymph node. The late image also showed one sentinel node in the right groin and one 
sentinel node in the left groin (Figure 1).  
Figure 1 
Preoperative anterior 
lymphoscintigraphic image
after intradermally injection
of TC -99m-nanocolloid
around the tumor (T) on the
glans of the penis showing
drainage to a prepubic
sentinel lymph node (I), an
inguinal sentinel lymph node
in the right groin (II) and an
inguinal sentinel nodes in the
left groin (III).   
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The location of the sentinel nodes was marked on the skin with ink in order to indicate the 
region to explore. Shortly before surgery, 1.0 ml patent blue dye (Blue patenté V, 
Laboratoire Guerbet, Aulnay-sous-Bois, France) was injected intradermally around the 
tumor. After dissection of blue colored lymph vessels and detection with a  probe 
(Neoprobe®, Johnson & Johnson Medical, Hamburg, Germany) the sentinel nodes were 
identified. One prepubic sentinel node and one inguinal sentinel node in the right groin 
were excised. A left inguinal lymph node dissection was carried out. Finally, the penis 
was partially amputated.   
Pathological evaluation of the sentinel nodes included hematoxylin-eosin and 
immunohistochemical staining using pankeratin and CAM 5.2 (Becton Dickinson, San 
Jose, California, USA).  
Both, the sentinel node in the right groin and the prepubic one revealed metastases. The 
inguinal lymph node dissection specimen of the left groin contained five lymph nodes. 
One of these nodes contained a metastasis. Based on these results, inguinal lymph node 
dissection on the right side (five nodes), prepubic dissection (no nodes), and bilateral 
pelvic lymph node dissections were performed (left four nodes, right three nodes). None 
of the twelve excised lymph nodes was involved.  
 
Discussion 
To date, elective inguinal lymphadenectomy is considered as standard management of 
clinically node negative groins in patients with penile carcinoma by many.4,5 When this 
policy would have been followed in this case, the tumor-positive sentinel lymph node 
would have been missed.  
During the last decades several penile lymphangiography and penile lymphoscintigraphy 
studies have been carried out. These studies did not reveal a prepubic sentinel lymph node 
so far.6-12 We have performed preoperative lymphscinigraphy in 140 penile carcinoma 
patients, in all cases showing inguinal drainage only.13 Also, we could not find a prepubic 
sentinel node described in lymphoscintigraphy studies for other malignancies such as 
melanoma and vulvar cancer. Unusual sites of sentinel nodes have also been reported in 
breast cancer and melanoma illustrating one of the advantages of lymphatic mapping: 
preoperative lymphoscintigraphy can identify lymph nodes outside the usual nodal 
basin.14,15
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Introduction 
A major problem in managing patients with penile squamous cell carcinoma (SCC) is the 
unreliability of clinical methods to detect regional lymph node metastasis at an early 
stage. There is a clinical urge to detect and treat these metastases as soon as possible 
because survival is clearly related to the extent of lymph node metastasis.  
Stage, grade of differentiation, depth of infiltration and presence of vascular invasion of 
the primary tumor are known to be predictive factors for nodal metastasis.1-4 However, 
relying solely on these characteristics for the decision to perform regional node dissection 
will lead to unacceptable false negative and false positive rates.1  
Prophylactic lymph node dissection in all patients leads to overtreatment in about 80% as 
a consequence of the low incidence of occult lymph node metastases.5 On the other hand, 
a wait and see policy harbors the risk of patients presenting with metastasis at a stage 
where cure is no longer possible.3,4
Dynamic sentinel node biopsy for penile SCC is a procedure that facilitates detection of 
occult metastasis in clinically node-negative inguinal regions at an early stage. This 
procedure decreases morbidity by preventing unnecessary lymph node dissections and 
removes tumor-positive nodes at the earliest possible moment.  
The dynamic sentinel node biopsy procedure for penile SCC was adopted in The 
Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital in 1994 and results have 
been published before.6,7 Since the success of this diagnostic procedure is determined by a 
low false negative rate, in this study our false negative cases are analyzed. Insight in these 
cases is essential to improve the procedure. 
 
Materials and Methods 
Between January 1994 and February 2003, 123 consecutive patients with penile SCC 
underwent dynamic sentinel node biopsy at our institute. The mean age was 64 years 
(range 28-90). The study group consisted of 109 bilateral clinically node-negative 
patients. In fourteen patients one side was tumor-positive as proven by fine-needle 
aspiration cytology. The tumor staging system according to the 1987 TNM classification 
for penile SCC was used.8 Clinical tumor stage was T2 in 104 and T3 in 19 patients. 
Patients were not eligible for the study if the tumor was staged as T1 or carcinoma in situ 
because of the assumed low risk of occult metastasis.  
Confirmatory lymph node dissection after negative sentinel node biopsy was not 
performed. Standard inguinal lymph node dissection with or without iliac node dissection 
was reserved for patients with proven lymph node metastasis.  
The two-day sentinel node biopsy protocol has been described in detail elsewhere.9 On the 
day before surgery, 0.3 to 0.4 ml 99mTechnetium-nanocolloid (Nanocoll®, Amersham 
Cygne, Eindhoven, the Netherlands) was injected intradermally at three or four sites 
around the tumor. The average radioactive dose was 66 MBq (range 36-131). Dynamic 
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anterior lymphoscintigraphy was performed during 20 minutes immediately after 
injection. Subsequently, five minute static images were obtained after 30 minutes and two 
hours post-injection. A dual-head gamma camera (ADAC Vertex®, Milpitas, California, 
U.S.A.) was used. Both anterior or posterior and lateral images were obtained. A hot spot 
in the inguinal region was considered to be a sentinel node if an afferent lymph channel 
was visualized or the hot spot was the first one seen in a sequential pattern or the hot spot  
was the only one depicted. The location of the sentinel node was marked on the skin with 
dye in order to guide detection with a gamma-ray probe (Neoprobe®, Johnson & Johnson 
Medical, Hamburg, Germany) during surgery. 
Shortly before surgery, 1.0 ml patent blue dye (Blue patenté V, Laboratoire Guerbet, 
Aulnay-sous-Bois, France) was injected intradermally around the tumor. Both tracers 
were used to identify the sentinel node.  
The sentinel node was harvested after dissection of blue lymphatic vessels and 
intraoperative detection of radioactivity with the gamma ray detection probe. Sentinel 
node biopsy was generally followed by treatment of the primary tumor during the same 
session.  
The sentinel nodes were bisected, formalin fixated, paraffin embedded and cut at six or 
more levels. Paraffin sections were stained with hematoxylin and eosin. 
Immunohistochemical staining using pankeratin and CAM 5.2 (Becton Dickinson, San 
Jose, California, USA) was added to the pathological assessment after the tenth procedure. 
All patients were seen at two-months intervals during the first two postoperative years, at 
three-months intervals in the third postoperative year and every six months thereafter. 
Median follow-up was 39 months (range 2-118). Two patients were lost to follow-up 
because of emigration after five and sixteen months respectively. 
The result of the procedure was considered positive if a tumor-positive node was found 
during the standard sentinel node biopsy procedure, within the limits of the protocol. This 
definition serves the clinical purpose best.10  
The result of the procedure was considered false negative when lymphatic dissemination 
came to light later on through recurrent disease. The standard definition of the false 
negative rate was used. It was calculated over the number of false negative results divided 
by the total of positive results plus the false negative results. 
 
Results 
Lymphoscintigraphy visualized at least one sentinel node in 121 of 123 (98%) patients. 
Lymphatic drainage to both groins was seen in 100 (83%) patients and unilateral drainage 
in 21 (17%). In 221 inguinal regions, 284 sentinel nodes were seen.  
Not all the hot spots that were defined as sentinel nodes could be surgically identified: a 
total of  261 (92%) sentinel nodes were harvested. One sentinel node was only palpable 
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(0.4%), three (1%) were only blue, 73 (28%) were only radioactive and 184 (70%) were 
both blue and radioactive.  
The sentinel node revealed metastasis in 28 out of 123 (23%) patients and was false 
negative in six. The false negative rate thus was 18% (6 of 34). Patient characteristics of 
the six false negative procedures and presumptive reasons for failure are presented in 
Table1. 
 
Table 1 
Characteristics of six false negative sentinel node procedures in patients with penile SCC. 
No. Age Stage Lymph node 
status 
 
   L                
R                      
Regional 
recurrence 
 
   L                
R 
Time to 
recurrenc
e 
(months) 
Survival
(months)
Patient 
Status 
Presumptive 
reason  for 
failure 
           
1 49 T2G3 SN+ NE - + 27 84 NED No tracer uptake 
by tumor 
blockage 
2 68 T2G3 SN- SN- + - 3 96 NED No tracer uptake 
by tumor 
blockage and 
rerouting 
3 73 T2G2 NE SN- - + 7 16 DOD No tracer uptake 
by tumor 
blockage and 
rerouting 
4 64 T2G1 SN- N1 + - 6 18 DOD No tracer uptake 
by tumor 
blockage and 
rerouting 
5 83 T2G1 SN+ SN- - + 7 14 DOD Sampling error 
by the pathologist
6 74 T3G1 SN- SNni - + 9 15 DOD Not all visualized 
hot spots were 
retrieved 
L: Left groin, R: Right groin, NED: No evidence of disease, DOD: Death of disease, NE: Not 
explored, SN+: Tumor-positive sentinel node, SN-: Tumor-negative sentinel node, SNni: Sentinel 
node not identified. 
 
In one of the false negative cases (case1) one groin was not explored because 
lymphoscintigraphy did not identify a sentinel node on this side. Twenty-seven months 
after lymphatic mapping an enlarged lymph node in this groin was noticed, which proved 
to be tumor-positive. In four other patients (cases 2, 3, 4 and 5) regional tumor recurrence 
was seen after tumor-free sentinel nodes were harvested from the same groin before. In 
one of these patients (case 5), additional serial sectioning and immunohistochemical 
staining of the sentinel node revealed metastasis after all. In the last patient (case 6) 
lymphoscintigraphy showed only slight uptake in the sentinel nodes. During surgery the 
count rate in the sentinel nodes was very low, about 1.5 times that of the background, and 
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the sentinel node could be identified on the right side. Nine months later the patient 
presented with a tumor mass in the unsuccessfully explored groin.  
 
Discussion 
A total of six patients out of a group of 34 with a tumor-positive groin had a false negative 
dynamic sentinel node biopsy. Although recurrences in this series occurred after a median 
interval of seven months, establishing the true incidence of false negative procedures 
requires a longer period of follow-up. Several lessons, however, can already be learned. 
First of all, when unilateral drainage is seen on the lymphoscintigram as was observed in 
case 1, one should be on the alert that non-visualization of a sentinel node in the 
contralateral groin may be caused by lymph node metastasis blocking the lymphatic flow 
(Figure 1). 
 
 
Figure 1 
Example of blockage: the
sentinel node (SN) in the right
groin is invaded by metastases.
The afferent lymphatic flow is
blocked by these metastases.
This sentinel node will not be
visualized on the scintigram.
The sentinel node in the left
groin will be visualized
correctly. 
Exploration of a non-visualized groin may reveal a blue vessel leading to a non-
radioactive sentinel node. Furthermore, intraoperative palpation of the wound facilitates 
finding of solid tumor-positive nodes which could not be detected by palpation through 
the skin.11 Recently, a scintigram of a patient with two unsuspected groins showed no 
sentinel node in the left groin and one in the right groin. This node was tumor-free. 
Exploration of the left groin and subsequent palpation of the wound revealed an enlarged 
node, which turned out to be tumor-positive. Exploration for blue vessels and 
intraoperative palpation of the wound now is a standard procedure in our sentinel node 
biopsy practice. In addition, inadequate injection of the radioactive tracer can also be the 
reason for unilateral drainage.9
In cases 2, 3 and 4, blockage and rerouting due to a sentinel node that is invaded by tumor 
is the presumptive cause for failure. The true sentinel node is bypassed and the tracer is 
diverted to another node: the so called “neo”-sentinel node (Figure 2). 
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Figure 2 
Example of blockage and
rerouting: the sentinel node
(SN) in the right groin is
invaded by metastases. The
afferent lymphatic flow is
blocked and diverted to another
node that is labeled as a so
called “neo”-sentinel node
(NeoSN). This node is falsely
visualized as the sentinel node
on the scintigram. The sentinel
node in the left groin will be
visualized correctly. 
Therefore again, palpation of the biopsy wound should always be performed. It is 
noteworthy that penile lymphoscintigraphy at our institute demonstrated inguinal drainage 
in all patients in whom the sentinel node was visualized. Like Cabañas, we never found 
pelvic or prepubic drainage.12 This is in contrast with the observations of Dewire et al,13 
recently referred by Jacobellis,14 who maintain that the glans and corporal body partly 
drain to the pelvic nodes. For that matter, 90% of the penile SCCs of our series involve 
the glans. 
Routine pathological analysis at our institute was adjusted after the tenth procedure 
because of the pathological sampling error (case 5). The nodes now are serially sectioned. 
Moreover, immunohistochemistry has been added to standard staining. No more 
pathological false negative results occurred since.  
Little radioactivity in the sentinel node is probably the reason of non-identification in case 
6. There is no obvious cause verifiable that explains the low level of radioactivity in this 
case. Nevertheless, to avoid low levels during the procedure, the interval between 
scintigraphy and surgery should not extend 24 hours because of the physical half-life of 
six hours of 99mTechnetium. One can argue what should be done after such an 
unsatisfactory procedure: lymph node dissection or close observation. The disadvantage 
of lymph node dissection is its high morbidity.15,16 Regarding close observation, we have 
always relied on a strict two-monthly follow-up. Because of sometimes unexpected fast 
inguinal outgrowth this schedule may have to be changed to monthly visits. 
Since 1999, ultrasonography with fine-needle aspiration cytology has been added as a 
routine preoperative examination in patients with clinically node negative groins. Modern 
ultrasonography can show changes in the architecture of impalpable nodes suggestive of 
metastases. Only patients with negative cytology are candidates for sentinel node biopsy. 
Experiences in other malignancies resulted in excellent sensitivity and specificity for 
detecting occult lymph node metastases.17,18 Improved patient selection can be achieved 
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and more accurate procedures can be performed by using ultrasound. In particular false 
negative cases caused by tumor blocking and rerouting will hopefully be avoided.    
To avoid false negative procedures some general rules remain. Combined use of a 
radioactive tracer and blue dye is mandatory for a high identification rate of the sentinel 
node.19 Like sentinel node procedures in other malignancies, the existence of a learning 
phase cannot be denied.20 Also, close cooperation and interaction between surgeons, 
radiologists, nuclear medicine physicians and pathologists is crucial.  
Finally, continued assessment and monitoring is necessary to investigate whether the 
modifications made will lead to a lower false-negative rate.  
 
Conclusions 
Important adaptations based on false negative results have been made in the dynamic 
sentinel node biopsy procedure for penile carcinoma at our institute. Pathological analysis 
has been extended by serial sectioning and immunohistochemical staining, and 
preoperative ultrasonography with fine-needle aspiration cytology has been added. 
Furthermore, exploration of groins with non-visualization on the scintigram and 
intraoperative palpation of the wound have been introduced. These changes will hopefully 
result in a reduced false negative rate. 
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Introduction 
Approximately 20% of clinically lymph node-negative penile carcinoma patients harbor 
occult inguinal lymph node metastases.1 Various approaches to detect occult nodal spread 
have been used and there is still much debate regarding what has to be considered the best 
management. The most invasive approach is elective inguinal lymph node dissection, and 
the least invasive is to watch and wait. The major disadvantage of elective dissection is its 
redundancy when the regional lymph node basin is not involved, which is the case in 80% 
of the patients.2,3 Another factor to be considered is the accompanying substantial 
morbidity. The disadvantage of a wait and watch approach is possibly a worse prognosis 
when tumor involved lymph nodes are treated after they become palpable during follow-
up.4-6
The sentinel lymph node concept in theory is an attractive approach in the management of 
penile cancer. At our institute, this technique has been used since 1994 and 140 
procedures have been performed since. Sentinel node biopsy in penile carcinoma proved 
to be of important diagnostic, prognostic and therapeutic value at the cost of only minor 
morbidity.7,8 An important caveat of the sentinel node procedure for penile carcinoma, 
however, is the event of a false-negative biopsy.9 A varying lymphatic drainage pattern 
could be one of the causes of these false-negative sentinel node procedures. To examine 
this, we evaluated the reproducibility of lymphoscintigraphy for lymphatic mapping in 
patients with penile carcinoma by assessing the location and number of sentinel nodes as 
depicted on two subsequent lymphoscintigrams. 
  
Materials and Methods 
Between January 2004 and December 2004, 20 clinically node negative T2-3N0-1 penile 
carcinoma were prospectively enrolled in this study. In 17 patients the primary lesion was 
still present, in three patients the lesion was excised several weeks before 
lymphoscintigraphy. The mean age of the patients was 65 years (range 40-84). Informed 
consent was obtained from all patients and the protocol was approved by the ethical 
committee of our institution. 
 
Imaging 
The two lymphoscintigrams were performed on the day and the following morning before 
surgery. For logistic reasons, two patients underwent both examinations and the operation 
on the same day. Twenty minutes after local anaesthesia by xylocaine 10% spray, an 
average net dose of 59 MBq (range 49-76) technetium-99m nanocolloid (Amsterdam 
Cygne, Eindhoven, the Netherlands) in a mean volume of 0.3 ml (range 0.2-0.3) was 
intradermally administered around the tumor with a 25-gauge needle. Injection was 
divided into 3 depots of approximately 0.1 ml. The tracer was administered proximally 
from the tumor or excision scar. For large tumors extending beyond the glans, the tracer 
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was injected in the prepuce. Shortly after injection, a 10-minute anterior dynamic study 
was performed with a dual-head gamma camera and subsequently, static anterior and 
lateral images were obtained at 30 minutes and two hours using simultaneous Co-57 flood 
source transmission scanning for orientation. The location of the sentinel node was 
determined using a 57Co marker and indicated on the skin with indelible ink. Just before 
the second lymphoscintigraphic study, a five-minute static image was obtained as a point 
of reference for the injection sites. Subsequently, the procedure described above was 
repeated in an identical fashion by the same investigator (R.A.V.O.).  
The mean interval between injection of the radiolabeled colloid for the first and second 
lymphoscintigram was 21 hours (4-26). The mean radioactivity of the second injection, 
calculated on the basis of net administered doses, was 62 MBq (range 42-74).  
 
Dynamic sentinel node biopsy 
Shortly before surgery, 1.0 ml patent blue dye (Blue Patenté V, Laboratoire Guerbet, 
Aulnay-sous-Bois, France) was intradermally injected around the tumor or excision scar. 
The sentinel node was identified and harvested after dissection of blue lymphatic vessels 
and detection of radioactivity with a gamma ray detection probe (Neoprobe®, Johnson & 
Johnson Medical, Hamburg, Germany) 
 
Data interpretation and analysis 
Lymphoscintigraphic images were evaluated with regard to similarity of depiction of 
draining lymph node basins and location and number of sentinel nodes. Criteria to 
distinguish the sentinel node from non sentinel nodes were visualization of an afferent 
lymphatic vessel leading from the injection site to the lymph node or, in case of multiple 
nodes with no afferent vessels seen on the lymphoscintigram, the first lymph node 
appearing in the basin. Radioactive count rates for the visualized sentinel nodes were 
measured on five-minutes anterior images by using the region-of-interest software linked 
to the gamma camera. Count rates were measured at three points in time: during the last 
image of the first lymphoscintigraphy, during the image obtained just before the second 
lymphoscintigraphy, and during the last image of the second lymphoscintigraphy. Count 
rates were calculated as the maximal number of counts per pixel. The count rate for hot 
spots visualized during the second lymphoscintigraphy was corrected for differences in 
the time between injection and acquisition of the last image, differences in net 
administered radioactivity dose, and residual radioactivity. The 95% confidence interval 
(CI) of the calculated reproducibility was determined by using binomial distribution. The 
paired count rates for each hot spot were plotted to determine the variability of lymphatic 
flow and tracer uptake. The correlation coefficient between the two sets of scintigraphic 
results was calculated. P < .05 was considered to indicate a statistically significant 
difference. In addition, the Bland-Altman method was used to determine the amount of 
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agreement between the count rates at the two scintigraphic examinations. A logarithmic 
data transformation was performed because the differences were proportional to the mean 
count rate 
 
Results 
At least one sentinel node was visualized in all patients on the first lymphoscintigram. A 
total of 56 sentinel nodes were observed in 38 basins, with a mean number of 2.8 nodes 
(range 2-5) per patient and a mean number of 1.5 nodes (range 1-4) per visualized basin. 
Drainage to both groins was observed in 18 patients. One of them showed also drainage to 
the prepubic area (Figure 1). Two patients had drainage to one groin only (one to the left 
groin and one to the right groin).  
The second lymphoscintigram revealed the same drainage pattern in all patients: the same 
number and side of nodal basins and the same number of sentinel nodes were visualized at 
identical locations, including the prepubic area (Table 1, Figure 1).  
 
Table 1 
Patients and lymphoscintigraphic data. 
 
Patient 
No. 
 
 
Age 
First scan 
 
Dose (MBq)     No. of SNs         No. of 
basins 
Second scan 
 
Dose (MBq)     No. of SNs         No. of 
basins 
1 53 54 3 2 56 3 2 
2 59 56 3 2 67 3 2 
3 63 59 2 2 67 2 2 
4 60 56 2 2 57 2 2 
5 53 64 2 2 64 2 2 
6 78 56 2 2 66 2 2 
7 69 63 2 2 70 2 2 
8 70 59 5 2 70 5 2 
9 69 53 3 2 74 3 2 
10 81 62 3 2 62 3 2 
11 74 76 4 2 60 4 2 
12 40 49 2 1 69 2 1 
13 79 53 3 2 59 3 2 
14 84 58 2 1 60 2 1 
15 49 64 2 2 42 2 2 
16 52 58 3 2 62 3 2 
17 51 63 4 2 66 4 2 
18 83 61 2 2 55 2 2 
19 60 65 4 2 67 4 2 
20 64 58 3 2 50 3 2 
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Figure 1 
Three paired sets of scintigraphic images demonstrate lymphatic drainage from the primary tumor (T) 
to the same nodal basins and the same sentinel nodes. A and B (two hour images obtained in a 83-
year-old man) show bilateral drainage to one inguinal sentinel node in the left groin and one sentinel 
node in the right groin (arrows in A). Besides the sentinel nodes two second-echelon nodes in the right 
groin and three second-echelon nodes in the left groin are visualized. C and D (15 minute images 
obtained in a 84-year old man) show unilateral drainage to two sentinel node (arrows in III) and one 
second-echelon node in the right groin.  
E and F (two-hour images obtained in a 52-year old man) show one sentinel node in the right groin, 
one sentinel node in the left groin and one prepubic sentinel node (arrows in V). Besides these three 
sentinel nodes, one second-echelon node in the left groin and one second-echelon node in the right 
groin are visualized.  
   
A C E
 
The reproducibility of penile lymphoscintigraphy thus was 100% (95% CI:83-100%) 
Radioactive count rates could be obtained of all 56 sentinel nodes. All hot spots visualized 
during the fist lymphoscintigram showed an increase in radioactivity after the second 
injection of the radiolabeled colloid  (Figure 2).  
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Figure 2
Count rates for each hot spot
(n = 56), as measured at three
points in time: (1.0) the late
five-minute image at initial
scintigraphy, (2.0) the starting
five-minute image just prior to
the second injection of the
colloid, and (3.0) the late five-
minute image at repeat
scintigraphy. 
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2
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The paired count rates for each hotspot are displayed in Figure 3.  
 
Figure 3 
Scatter plot showing correlation
between the count rates of each
sentinel node, as obtained on the
late image of the first and second
lymphoscintigraphic examinations
(Pearson r = 0.688, P < 0.0001).  
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The Pearson correlation coefficient for the count rates at the first and the second 
scintigraphic examinations was 0.69 (P < .0001). The differences in count rates between 
the first and second scintigraphic examinations were plotted against their means after 
logarithmic transformation according to the Bland-Altman method (Figure 4).  
 
 
 
The mean difference of the antilogs was 1.07 (95% CI: 0.16-7.0). This means that for 
about 95% of the cases the count rate of the second measurement will be between 0.16 
and 7 times the first measurement. 
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Figure 4 
Scatter plot illustrating agreement
of count rates of sentinel nodes at
two scintigraphic studies, as
calculated with the Bland-Altman
method after logarithmic data
transformation. The straight
horizontal line indicates the mean
difference (0.03, 95% CI:  -0.08 -
0.14). The dashes lines represent
the mean + or –  two standard
deviations, i.e.  the upper (0.84,
95% CI:  0.65 - 1.03) and lower
limits of agreement (0.79, 95%
CI:  -0.98 - -0.60). This analysis
quantifies the difference in lymph
node radiocolloid uptake during
the second scintigraphic
examination. 
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Discussion 
Variability in lymphatic drainage patterns might explain false-negative results in sentinel 
node biopsy. In the present study, however, this assumption is enervated by the 100% 
concordance of the two lymphoscintigrams for the depiction of nodal basins, number of 
sentinel nodes, and sentinel node location. Moreover, all hotspots that were visualized 
during the first lymphoscintigram showed increase in radioactivity after repeat injection of 
the radiolabeled colloid and the correlation for the count rates at the first and the second 
scintigraphic examinations was significant. Nevertheless it is noteworthy that in two 
nodes (in two different patients) the uptake of the radiolabeled colloid at the first and 
second lymphoscintigram was not equal. Both nodes were clearly hotter in the first study. 
This variability, probably caused by differences in the lymphatic flow, may result in 
scintigrams that are not reproducible when the uptake of the radiolabeled colloid is too 
low to be perceived.  
In contrast to the excellent reproducibility of lymphoscintigraphy, variations between 
lymphatic mapping with radiolabeled colloid and mapping with blue dye occur fairly 
often, in our series in 30% of cases.7 This may be caused by differences in the 
characteristics of the two tracers, the site of injection, and the difference in injected 
volume. For instance, blue dye can enable visualization of an afferent lymphatic vessel 
leading to a sentinel node without being phagocytosed by the macrophages of that node as 
is the case with the radiolabeled colloid. The fact that in general different physicians 
administer the radiolabeled colloid and blue dye, may result in differences in injection 
technique and injection sites. Finally, the injected volume of blue dye is often greater than 
the volume of the radiopharmaceutical, which also can be the cause of a varied mapping. 
The two lymphatic mapping techniques seem complementary. But even with the  use of 
two tracers, some sentinel nodes may remain concealed, with the risk that nodal 
metastases are missed. The main reason for this event most likely is a sentinel node with 
massive involvement, prohibiting inflow and uptake of tracers.10 This phenomenon 
probably explains the majority of our false-negative cases.9 Preoperative ultrasonography 
may help to identify such grossly involved lymph nodes11 Modern ultrasonography can 
show changes in the architecture of impalpable nodes suggestive of metastases. In 
addition, intraoperative palpation of the explored area might reveal these firm lymph 
nodes that could not be palpated through the skin.9  
Three investigators have tested the reproducibility of lymphoscintigraphy before. In a 
study in melanoma patients by Kapteijn et al, in three of 25 patients (12%), the exact 
number of sentinel nodes could not be reproduced in a repeat lymphoscintigraphy.12 
Mudun et al showed concordance between two lymphoscintigraphies in 11 (85%) of 13 
patients with melanoma.13 Finally, Tanis et al found a 100% reproducibility of 
lymphoscintigraphy in 25 patients with breast cancer.14  
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Besides small variations in site of injection and injection volume, several other 
explanations for the limited reproducibility in melanoma were considered, such as 
previous physical exertion, body hydration, and variation in oncotic and hydrostatic 
pressure of blood. 
Finally, it was hypothesized that the wound healing process (all patients underwent prior 
excision of their primary lesion) influenced the lymphatic drainage of the operated area to 
some extent. The 100% reproducibility rate in breast cancer was explained by the fact that 
an intra-tumoral injection was performed instead of injecting the isotope around the 
excision scar, as is typically done in scintigraphy of melanoma. Notable in this regard is 
the fact that patients who had already undergone excision biopsy of the breast cancer were 
excluded.   
The 100% reproducibility of penile lymphoscintigraphy is on one hand unexpected for, 
like in melanoma, also in penile carcinoma several injections around the primary lesion (n 
= 17 in our series) or excision scar (n = 3 in this series) are given. On the other hand it can 
be hypothesized that the relatively simple lymphatic drainage pattern of the penis explains 
the high reproducibility, for most lymphatics tend to drain to a few collecting lymphatic 
vessels which are located on the dorsal side of the penis.15 With these considerations in 
mind it would be interesting to compare results of paired lymphoscintigraphic 
examinations performed before and after excision of a penile carcinoma. A substantial 
portion of our patients already have their primary tumor excised elsewhere. It may be 
presumed that this patient group can also be safely offered a sentinel node biopsy.  
 
Conclusion 
The results of the present study indicate that lymphoscintigraphy in patients with penile 
carcinoma has a 100% reproducibility in the assessment of inguinal and prepubic drainage 
in all twenty patients studied. Our data suggest that intra-individual variability in 
lymphatic drainage is an unlikely explanation for false-negative results of sentinel node 
procedures in penile carcinoma. 
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Introduction 
Approximately 20% of clinically node-negative patients with penile squamous cell 
carcinoma (SCC) harbor metastases in their inguinal lymph nodes.1 Non-invasive methods 
to detect these metastases are unreliable. However, there is a clinical need to find occult 
metastases at the earliest possible stage because survival is related to presence and extent 
of nodal involvement.2,3  Optimal management of patients with clinically node-negative 
groins is controversial. A surveillance policy harbors the risk of patients presenting with 
metastasis at a stage where cure is no longer possible. On the other hand, early inguinal 
lymphadenectomy in all clinically node negative patients is unnecessary in up to 80% of 
cases and is associated with substantial morbidity.4 Better staging procedures thus are 
mandatory to improve detection of occult metastasis and to decrease the number of 
unnecessary lymph node dissections. 
Recently, two methods have emerged to detect clinically occult metastases. The first is 
dynamic sentinel node biopsy (DSNB). DSNB is a minimally invasive procedure that 
enables detection of microscopic lymph node invasion in clinically node-negative regional 
basins. The sentinel node is the first lymph node on the direct drainage pathway from a 
primary tumor and, conceptually, tumor involvement of this node raises the possibility of 
further metastatic spread of the rest of the regional lymph nodes. After localization with 
the aid of preoperative lymphoscintigraphy and intra-operative tracing with a gamma-ray 
probe and vital dye, excision of the sentinel node is performed for histological assessment. 
Only patients with tumor-positive sentinel nodes undergo complimentary inguinal 
lymphadenectomy. DSNB is nowadays practiced as an important staging tool in various 
solid cancers, such as breast cancer and melanoma.5,6 DSNB for penile SCC was adopted 
at our institute in 1994 and results have been published before.7,8  
The second method for detection of occult lymph node metastases involves the use of high-
resolution ultrasound (US). Thanks to the high resolution probes, US scanning is increasingly 
reliable in detecting occult metastases. Modern US not only visualizes alteration in size, shape 
and contour of lymph nodes but also depicts changes in the cortical and hilar morphology and 
texture that can reflect the presence of underlying metastasis.9 Changes in the architecture of 
the node occur before the node enlarges and these are identified by the radiologist. Due to 
overlap of sonographic features of benign and suspicious lymph nodes, fine-needle aspiration 
cytology (FNAC) of sonographically suspicious nodes provides a more definitive diagnosis 
than US alone. Potential applications have been demonstrated in a number of malignancies.10-
13 US-guided FNAC was introduced at our institute as a pre-DSNB examination to improve 
staging of clinically node negative penile SCC patients. The aim of the current study was to 
assess the value of this approach. 
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Material and Methods 
Between 2001 and 2004, penile SCC patients scheduled for DSNB were included in this 
study. The mean age was 63 years (range 34-82). Median follow-up was 18 months (range 
2-36). In three patients, only one inguinal side was clinically node-negative. The 1987 
TNM classification for penile SCC was used for staging.14 Clinical tumor stage was T2 in 
36 and T3 in seven patients. Patients were not eligible for the study if the tumor was 
staged as T1 or carcinoma in situ because of the assumed low risk of occult metastasis.  
The radiologist performing the high resolution US and US-guided FNAC had already 
gained experience with the technique in breast cancer patients at our institute. Eighty-
three clinically node-negative groins were sonographically examined with a 10-13 MHz-
1.5D transducer (Siemens Elegra, Erlangen, Germany). Lymph nodes were considered 
suspicious according to Vassallo’s criteria. (Figure 1).9  
 
Figure 1 
Sonomorphologic lymph node features according to Vassallo et al.9: lymph node shape (length / width 
ratio (L/W)), peripheral hypo-echoic cortex (normal, concentrically wide or eccentrically wide) and 
central echogenic hilus (normal, narrow or absent). Suspicious features for nodal involvement are a 
L/W< 2, a concentrically/eccentrically wide cortex and a narrow to absent hilus.  
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←     L     → 
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FNAC was performed with a 23-gauge (0.6 mm) needle. FNAC was performed on 
suspicious nodes only (Figure 2a and Figure 2b) in an outpatient setting. 
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Figure 2 
Figure 2a. US image of suspicious node with eccentrically wide cortex (arrow). 
Figure 2b. US image of FNAC of the same node (arrow indicates aspiration needle). 
 
If more than one node was detected, the radiologist generally aspirated the most 
suspicious one. This usually meant that the node with the most atypical cortex was 
aspirated. The aspirated material was both air-dried and alcohol-fixed and prepared for 
May Grunwald Giemsa and Papanicolau staining. If FNAC showed tumor cells, complete 
inguinal lymphadenectomy on the positive groin was performed. The groin underwent 
DSNB if FNAC was not performed or did not show tumor cells. The two-day DSNB 
protocol has been described in detail previously.15 Briefly, lymphoscintigraphy was 
performed the day before surgery and the location of the sentinel node was marked on the 
skin. A gamma-ray detection probe (Neoprobe®, Johnson & Johnson Medical, Hamburg, 
Germany) and patent blue dye (Blue patenté V, Laboratoire Guerbet, Aulnay-sous-Bois, 
France) were used to identify the sentinel node intra-operatively. After harvesting, the 
sentinel node was bisected, formalin fixated, paraffin embedded and cut at six or more 
levels. Paraffin sections were stained with hematoxylin and eosin, and 
immunohistochemical examination was carried out using pankeratin and CAM 5.2 
(Becton Dickinson, San Jose, California, USA). Complementary inguinal 
lymphadenectomy was performed when the pathology evaluation revealed metastasis 
approximately four weeks after DSNB. All patients were seen at two month intervals 
during the first two postoperative years and every three months thereafter. No patients 
were lost to follow-up 
 
Results 
The mean number of lymph nodes visualized on US was 1.8 per groin (range 0-6). Thirty-
thirty four groins (41%) were ultrasonographically suspicious and were aspirated. Nine of 
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these aspirates were found to contain tumor cells. In the other 25, FNAC showed normal 
lymphoid cells or no cells at all. DSNB was performed on 74 groins. In fourteen of these 
groins, the sentinel node was tumor-positive. Metastases detected by US-guided FNAC 
were larger than 2mm. Ten of fourteen groins that were positive by DSNB contained 
micrometastasis (defined as a metastasis smaller than 2mm). Complete inguinal 
lymphadenectomy was performed in the nine groins in which FNAC was tumor-positive 
and in the fourteen groins with a tumor-positive sentinel lymph node. Nine of 23 groins 
harboring occult metastases could thus be identified by using US-guided FNAC. The 
results of the study are shown in a flowchart (Figure 3).  
 
  
 
 
 
 
There were no false-positive results. These findings result in a sensitivity of 39% (9/23) 
and a specificity of 100% (60/60). DSNB could be avoided in 39% of the positive groins. 
Altogether, groins on which a DSNB-procedures was performed was reduced by 11% 
(9/83). No false-negative dynamic sentinel node procedure came to light during follow-
up. No complications occurred as a result of US-guided FNAC.  
Figure 3 
Results of the study. LND
= Lymph node dissection 
* In one patient bilateral 
inguinal metastases and in 
seven patients unilateral 
inguinal metastases were 
detected by US-guided 
FNAC. ** The 14 positive 
nodes after DSNB that 
were not detected by 
US-guided FNAC 
consisted of seven nodes 
(all micrometastases) of 
the groins not initially 
suspicious on US, and 
seven nodes (three 
micrometastases and four 
macrometastases) of the 
groins initially suspicious 
on US.  
 
Discussion 
The sensitivity of US-guided FNAC to reveal clinically occult lymph node metastases in 
this study was 39% with a 100% specificity. In contrast to penile cancer, US-guided 
FNAC has been used extensively in assessing lymph nodes in other malignancies such as 
breast cancer and melanoma. 11-13 Sensitivity and specificity rates in our study are about 
the same as reported for these tumors. The sensitivity of  39% demonstrates that US- 
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FNAC cannot replace DSNB. However, US-guided FNAC is a useful tool for 
preoperative screening of the clinically node negative groins in patients with penile cancer 
scheduled to undergo DSNB. By detecting occult metastases, patients can immediately be 
scheduled for complete inguinal lymphadenectomy, avoiding unnecessary DSNBs in 
groins with a  positive node as proven by US-guided FNAC. Despite the advantages of 
DSNB as not having to perform a lymph node dissection in all clinically node negative 
groins the technique is burdened by a postoperative complication rate of ~10% and in case 
of sentinel node positivity it is -at least at our institute- not completed by complementary 
lymph node dissection within the same surgical section. The implementation of non-
invasive methods for preoperative staging might improve the quality of live of patients 
and reduce the economic costs of penile carcinoma management.  
One is tempted to believe that US-guided FNAC as a pre-DSNB examination will 
decrease the false-negative rate of the DSNB procedure which is 18% in our hands.16 The 
commonest cause of a false-negative DSNB procedure is gross involvement of the 
sentinel node by tumor cells which prohibits tracer uptake with a false-negative procedure 
as a result.17 These nodes in particular might be detected by US-guided FNAC. It is note 
worthy that since the introduction of a pre-DSNB ultrasound in 2001 no more false-
negative DSNB procedure occurred at our institute.  
US-guided FNAC also has a place during follow-up after DSNB. Nodal recurrences, which 
can occur after a false-negative DSNB procedure, might be detected earlier when compared to 
physical examination. In our series, metastases in ten inguinal regions were not detected by 
US-guided FNAC. Several causes for these false-negative results can be mentioned. Firstly, 
the lymph node may appear abnormal and indeed contain metastatic disease, but the aspirate 
may fail to extract abnormal cells. This relates to erroneous sampling and can be 
difficult to overcome in a node with a small metastasis where placement of the needle is 
crucial. Secondly, microscopic small foci of metastatic disease might simply be beyond 
the resolution of the transducer and thus not show up on the images.10 
In order to improve the efficiency of ultrasound scanning, the future effort should focus 
on the reduction of false-negative results. To this end, at least two strategies might be 
useful. First, the introduction of echogenic contrast may increase ultrasound scan 
diagnostic power by allowing the identification of indirect features of lymph node 
metastases. Second, increasing the ultrasound probe ultra-frequency might ameliorate US 
scan resolution power, thus allowing lesions even smaller than two mm to be detected.11 
In addition, a learning phase of the radiologist performing US-guided FNAC cannot be 
denied. 
Recently, an other technique has emerged with the potential to identity occult lymph node 
metastases: magnetic resonance lymphangiography. By using an infusion of ultra small 
particles which are taken up homogeneously by functioning macrophages in normal 
nodes, foci of metastasic disease show as filling defect i.e. negative contrast on 
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subsequent images. This technique, though still largely experimental, showed promise 
with high specificity and sensitivity in prostate cancer and might also be applicable 
identifying occult lymph node metastases in other cancers.10,18
 
Conclusion 
The sensitivity of US-guided FNAC to detect clinically occult lymph node metastases in 
patients with penile cancer scheduled for DSNB is 39% with a 100% specificity. This 
means that in 11% of the groins a DNSB procedure could be avoided in favor of direct 
inguinal node clearance for proven nodal involvement. Moreover, no more false-negative 
DSNB procedures occurred after the introduction of US-guided FNAC as a pre-DSNB 
screening. US-guided FNAC is thus a useful tool for preoperative screening of the groin 
in patients with penile cancer scheduled to undergo DSNB. We have incorporated this 
technique in our routine DSNB-protocol. 
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Introduction 
The pattern of dissemination of penile squamous cell carcinoma is predominantly 
lymphogenic to the inguinal nodes.1 The status of regional lymph nodes is a powerful 
predictor of survival.2 Management of patients with proven inguinal metastases is 
straightforward and consists of treatment of the primary lesion and regional lymph node 
dissection.3 Treatment of individuals with impalpable nodes, however, has been subject of 
debate for many years. Approximately 20% of clinically node-negative patients with 
penile carcinoma harbor metastases in their inguinal lymph nodes.4 As a consequence, 
routine elective inguinal lymph node dissection leads to overtreatment in the majority of 
patients. Furthermore, this procedure is associated with substantial morbidity.5 On the 
other hand, a wait and see policy carries the risk of patients presenting with metastasis at a 
stage when cure is no longer possible. 
Biopsy of the sentinel lymph node has emerged as a potential alternative in the 
management of clinically node-negative penile carcinoma. The sentinel node is defined as 
the node that receives lymphatic drainage directly from a specific tumor site. Only 
patients with tumor-positive sentinel nodes undergo additional standard inguinal 
lymphadenectomy. Sentinel node biopsy is an attempt to diminish the exposure to the risk 
of complications without jeopardizing the oncological outcome. At our institute, this 
technique was introduced in 1994 and results have been previously published.6,7
To localize the sentinel node preoperatively, lymphoscintigraphy is performed after 
peritumoral injections of 99mTc-labeled nanocolloid tracers. Intraoperatively, the sentinel 
node can be identified with the aid of a blue dye and a hand-held gamma-ray detection 
probe.  
Unfortunately, there is not always tracer uptake in a groin. Groins with non-visualization 
pose a dilemma when sentinel node biopsy is contemplated.     
The purposes of this study were to determine the incidence and possible causes of 
scintigraphic non-visualization of sentinel nodes and its consequences for the management 
of the inguinal region. 
  
Patients and Methods 
From 1994 to 2003, 123 consecutive patients with bilateral clinically node-negative penile 
cancer were prospectively enrolled in this study. Patients were not eligible for the study if 
the primary tumor was staged as T1 or carcinoma in situ, because of the assumed low risk 
of occult metastasis. The histological type was squamous cell carcinoma in all patients.  
The day before surgery, lymphoscintigraphy was performed after intradermal injection of 
nanocolloid (Amersham Cygne, Eindhoven, the Netherlands) labeled with 99mTc. The 
average net dose of the radioactivity was 66MBq (range 36-131MBq). The tracer was 
administered at three or four sites around the tumor with a total volume of 0.3 ml to 0.4 
ml. Anterior dynamic lymphoscintigraphy was performed during 20 minutes immediately 
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after injection. Images were obtained using a dual-head gamma camera (ADAC, Milpitas, 
CA, USA) with low energy high-resolution collimators. Subsequently, five-minutes 
anterior and lateral static images were obtained after 30 minutes and two hours post-
injection. A hot spot in the inguinal region was considered to be a sentinel node either if 
an afferent lymphatic channel was visualized, the hot spot was the only one in the basin, 
or the hot spot was the first one seen in a sequential pattern. The location of the sentinel 
node was marked on the skin with ink using real time imaging and a 57Co-pen.  
Shortly before surgery, 1.0 ml patent blue dye (Blue Patenté V, Laboratoire Guerbet, 
Aulnay-sous-Bois, France) was intradermally injected around the tumor. The sentinel 
node was identified and harvested after dissection of blue lymphatic vessels and detection 
of radioactivity with a gamma ray detection probe (Neoprobe®, Johnson & Johnson 
Medical, Hamburg, Germany). Sentinel node biopsy was followed by treatment of the 
primary tumor during the same session. Sentinel nodes were bisected, formalin fixated, 
paraffin embedded and cut at six or more levels. Paraffin sections were stained with 
hematoxylin and eosin. Immunohistochemical staining using pankeratin and CAM 5.2 
(Becton Dickinson, San Jose, CA, USA) was added after the tenth procedure. Standard 
inguinal lymph node dissection was reserved for patients with a proven lymph node 
metastasis. Sentinel node-negative patients were observed. All patients were followed 
regularly at The Netherlands Cancer Institute with intervals of two months during the first 
two years after diagnosis, intervals of three months in the third year and every six months 
thereafter. Median follow-up was 52 months (range 5-129). Univariate analyses using the 
two-sample t test and chi-square test were performed to compare data of patients with 
bilateral visualization of hot spots and data of those without bilateral visualization.  
 
Results 
Lymphatic drainage to both groins was seen in 98 (79%) patients, unilateral drainage in 
23 (19%) patients and no drainage at all in two patients (2%). So, in 27 (11%) of 246 
groins, no sentinel node was visualized. Exploration for sentinel nodes was omitted in 19 
of these 27 non-visualized groins and in one visualized groin in which there was no intra-
operative radioactive count rate above the background count rate. In one of these 20 
groins tumor involved nodes became palpable during surveillance (Figure 1).  
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Figure 1 
Scintigraphic findings in 123 patients. 
Eight groins with lymphoscintigraphic non-visualization were explored making use of 
blue dye mapping. In four of these groins sentinel nodes could be found of which one 
contained metastasis. The visualization group (bilateral visualization) and non-
visualization group (unilateral and bilateral non-visualization) were compared with 
respect to administered tracer dose, patient age, and T-stage and grade of the primary 
tumor (Table 1).  
 
Table 1 
Characteristics of patients with bilateral visualization and patients with unilateral and no visualization 
on routine lymphoscintigraphy. 
 bilateral visualization  unilateral non-visualization (n = 
23) and bilateral non-visualization 
(n = 2) 
p-value 
Number of patients 98 25   
Tracer dose (MBq) 68 (SD 17) 59 (SD 15) 0.01 
Age 65 (SD 14) 62 (SD 13) 0.29 
T-stage    
2 83 20 0.57 
3 15 5  
Tumor grade    
I 50 10 0.59 
II 37 11  
III 11 4  
 
A statistical significant difference was found for the amount of administered tracer dose (p 
= 0.01). A total of 293 sentinel nodes were removed from 226 explored basins. The 
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sentinel node(s) was tumor-free in 97 patients and tumor-positive in the remaining 26 
patients (21%). Six patients had bilateral sentinel node involvement. Thirty-two 
complementary lymph node dissections were performed in the 26 sentinel node-positive 
patients.  
Discussion 
This study shows lymphoscintigraphic non-visualization of sentinel nodes in 11% of the 
mapped groins. At our institute, a unilateral sentinel node on the scintigram was initially 
interpreted as a normal physiological phenomenon and it was hypothesized that non-
visualization meant that the tumor drained to one groin only. After the occurrence of a 
tumor-positive node in the non-visualized groin of a patient with unilateral drainage 27 
months after lymphoscintigraphy we now no longer consider unilateral drainage a normal 
and innocent phenomenon but explore the non-visualized groin in such cases. This 
approach may reveal a blue vessel leading to a non-radioactive non-blue involved sentinel 
node. Blocking of afferent lymph vessels by tumor cells is considered to preclude tracer 
uptake in these nodes with a false-negative procedure as a result. Intra-operative palpation 
of the wound may facilitate finding suspicious enlarged or firm nodes involved by tumor 
which could not be detected by palpation through the skin.  
In addition, ultrasonography with fine-needle aspiration cytology has been added as a 
routine preoperative examination.8 Involved nodes causing non-visualization in particular 
might be detected by this methodology. Recently, lymphoscintigraphy in a patient with 
two clinically node negative-groins showed one sentinel node in the right groin and none 
on the left side. The sentinel node on the right side was tumor-free. Exploration on the left 
side revealed a suspicious unstained node that turned out to be tumor-positive. We now 
have explored eight non-visualized ultrasonographically negative groins and searching for 
blue vessels and palpation revealed sentinel nodes in four of them. It might be possible 
that in cases in which even after exploration no sentinel nodes could be found, unilateral 
drainage is physiologic. Non-visualization in our study appeared to be influenced by the 
dose of the injected tracer. For optimal results therefore it is important that the 
administered dose of activity is sufficient, i.e. at least 60 MBq. In contrast to penile 
carcinoma several studies in breast cancer deal with non-visualization.9-13 Also in this 
tumor non-visualization proved to be related to the tracer dose while patient age, injection 
volume and a high nodal tumor load were found as additional prognostic variables as well. 
Since lymphatic mapping in penile carcinoma like in other skin tumors is fast, small tracer 
volumes (0.3-0.4 ml) are generally injected in order not to influence normal physiology.14 
The effect of different injection volumes therefore, could not be analyzed in this study. 
Regarding high nodal tumor load as a cause for non-visualization it is noteworthy that in 
our series of unilateral cN1 penile carcinoma patients (n=17) no drainage to the affected 
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side was seen in four patients while drainage to the clinically unaffected side was seen in 
all.15  
In two patients no drainage at all was observed. Images after seven and 19 hours 
respectively, still were negative. Even re-injection of the tracer did not reveal sentinel 
nodes on the scintigrams. In one of these patients the penis was grossly edematous 
because of infection of the primary tumor and it might be hypothesized that lymph 
drainage was blocked for that reason. In the other patient no obvious cause could be 
found. Since surveillance in clinically node-negative patients was our standard of care 
before the advent of sentinel node biopsy, the groins in these two patients were not 
dissected. They remain without recurrence at last follow-up.  
 
Conclusions 
Preoperative lymphoscintigraphy after peritumoral injection of 99mTc-nanocolloid for 
penile carcinoma results in a visualization rate of 89% of the groins. Visualization appears 
to depend on the administered tracer dose while tumor load in the lymph nodes also may 
play a role. If no sentinel node is visualized it is worthwhile to explore the groin making 
use of blue dye mapping. Intra-operative palpation may reveal suspicious unstained nodes, 
involved by tumor. Pre-operative ultrasonography with fine-needle aspiration cytology 
has been added to our protocol. Impalpable grossly involved tumor-positive nodes causing 
non-visualization in particular might be detected by this methodology. If in the end, a 
sentinel node is not found, it can be disputed if lymph node dissection should be done or 
surveillance with close observation should be recommended.    
 
References 
 1.  Cabañas, R. M.: Anatomy and biopsy of sentinel lymph nodes. Urol Clin North Am, 19: 267, 
1992 
 2.  Soria, J. C., Fizazi, K., Piron, D. et al.: Squamous cell carcinoma of the penis: multivariate 
analysis of prognostic factors and natural history in monocentric study with a conservative 
policy. Ann Oncol, 8: 1089, 1997 
 3.  Solsona, E., Algaba, F., Horenblas, S. et al.: EAU Guidelines on Penile Cancer. Eur Urol, 46: 1, 
2004 
 4.  Abi-Aad, A. S. and deKernion, J. B.: Controversies in ilioinguinal lymphadenectomy for cancer 
of the penis. Urol Clin North Am, 19: 319, 1992 
 5.  Bevan-Thomas, R., Slaton, J. W., and Pettaway, C. A.: Contemporary morbidity from 
lymphadenectomy for penile squamous cell carcinoma: the M.D. Anderson Cancer Center 
Experience. J Urol, 167: 1638, 2002 
 6.  Horenblas, S., Jansen, L., Meinhardt, W. et al.: Detection of occult metastasis in squamous cell 
carcinoma of the penis using a dynamic sentinel node procedure. J Urol, 163: 100, 2000 
 7.  Tanis, P. J., Lont, A. P., Meinhardt, W. et al.: Dynamic sentinel node biopsy for penile cancer: 
reliability of a staging technique. J Urol, 168: 76, 2002 
 8.  Kroon, B. K., Horenblas, S., Deurloo, E. E. et al.: Ultrasonography-guided fine-needle 
aspiration cytology before sentinel node biopsy in patients with penile carcinoma. BJU Int, 95: 
517, 2005 
 9.  Tanis, P. J., van Sandick, J. W., Nieweg, O. E. et al.: The hidden sentinel node in breast cancer. 
Eur J Nucl Med Mol Imaging, 29: 305, 2002 
94
  Non-visualization of sentinel lymph nodes 
 10.  Brenot-Rossi, I., Houvenaeghel, G., Jacquemier, J. et al.: Nonvisualization of axillary sentinel 
node during lymphoscintigraphy: is there a pathologic significance in breast cancer? J Nucl 
Med, 44: 1232, 2003 
 11.  Krausz, Y., Ikeda, D. M., Jadvar, H. et al.: Non-visualization of sentinel lymph node in patients 
with breast cancer. Nucl Med Commun, 22: 25, 2001 
 12.  Birdwell, R. L., Smith, K. L., Betts, B. J. et al.: Breast cancer: variables affecting sentinel lymph 
node visualization at preoperative lymphoscintigraphy. Radiology, 220: 47, 2001 
 13.  Moffat, F. L., Jr., Gulec, S. A., Sittler, S. Y. et al.: Unfiltered sulfur colloid and sentinel node 
biopsy for breast cancer: technical and kinetic considerations. Ann Surg Oncol, 6: 746, 1999 
 14.  Morton, D. L., Wen, D. R., Wong, J. H. et al.: Technical details of intraoperative lymphatic 
mapping for early stage melanoma. Arch Surg, 127: 392, 1992  
 15.   Kroon BK, Horenblas S, Meinhardt et al: Dynamic sentinel node biopsy in penile 
         carcinoma: evaluation of 10 years experience. Eur Urol,47: 601, 2005 
 
  
95
 
Chapter 11 
 
 
 
 
 
Dynamic sentinel node biopsy in penile carcinoma: evaluation of 10 
years experience 
 
 
 
 
Bin K. Kroon, Simon Horenblas, Wim Meinhardt, Henk G. van der Poel, Harm van 
Tinteren, Renato A. Valdés Olmos and Omgo E. Nieweg 
 
Departments of Urology, Nuclear Medicine and Surgery 
The Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital 
Amsterdam, the Netherlands 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Eur Urol, 47: 601, 2005 
Chapter 11   
Introduction 
The management of impalpable nodes in patients with penile carcinoma has been subject 
of controversy for many years and various approaches have been used. The most invasive 
approach is elective bilateral inguinal lymph node dissection, and the least invasive a 
“wait and see” policy. A significant disadvantage of the former is the accompanying 
morbidity. Moreover it is considered unnecessary, as the regional lymph node basin is not 
tumor-affected in up to 80% of the patients.1 The disadvantage of a wait and see approach 
is a possible poorer prognosis at the time that tumor involved lymph nodes become 
palpable during follow-up.2,3 Several investigators have tried to solve the problem by 
setting up selection criteria of patients in whom elective inguinal lymphadenectomy is 
indicated. Histopathological characteristics of the primary tumor, such as depth of 
invasion (T-stage), differentiation grade, and the presence of vascular invasion, have been 
found to be of predictive value for occult lymph node metastases. 4,5 However, using these 
predictors to define patient populations still results in substantial false-positive and false-
negative rates. Therefore, nodal tissue analysis remains a necessity. 
Dynamic sentinel node biopsy provides a means of assessing lymph node status through a 
minimally invasive procedure. Only one node to a few at the most, considered pivotal in 
the spread of the disease, are removed with the aid of preoperative lymphoscintigraphy, 
intra-operative gamma ray detection, and a vital dye. Dynamic sentinel node biopsy is an 
attempt to diminish the risk of complications without jeopardizing the oncological 
outcome. Only patients with tumor-positive sentinel nodes undergo additional 
complementary inguinal lymph node dissection. At our institute, this technique has been 
used since 1994. Our initial experiences have been published previously.6,7 To date, 140 
sentinel node procedures have been performed and the median follow-up has surpassed 
four years. The present study was undertaken to evaluate reliability, benefits, untoward 
sequelae, and clinical impact of this novel procedure. 
 
Patients and methods 
Patients  
From January 1994 to April 2004, 123 consecutive patients with bilateral clinically node-
negative penile cancer were prospectively enrolled in this study. In addition, 17 unilateral 
node positive patients (N1) based on physical examination, ultrasonography and fine-
needle aspiration cytology were entered. These patients underwent sentinel node biopsy 
for the clinically unaffected side. Patients were not eligible for the study if the primary 
tumor was staged as T1 or carcinoma in situ, because of the assumed low risk of occult 
metastasis. The histological type was squamous cell carcinoma in all patients. The 
characteristics of patients and primary tumors are shown in Table 1. 
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 Bilateral clinically 
node-negative 
Unilateral clinically 
node-negative 
Number of patients 123 17 
Mean age (range) 64  (30-90) 59 (28-81) 
T-stage   
     T2 103 12 
     T3 20 5 
Tumor grade   
     I 60 3 
     II 48 9 
     III 15 5 
Vascular invasion   
     Absent 113 15 
     Present 10 2 
Table 1  
Characteristics of patients and
primary tumors of the 123
bilateral clinically node-
negative and 17 unilateral
clinically node-negative penile
carcinoma patients. 
 
Lymphoscintigraphy, surgery, and pathology 
The day before surgery, lymphoscintigraphy was performed after intradermal injection of 
nanocolloid (Amersham Cygne, Eindhoven, the Netherlands) labelled with 99mTc. The 
average net dose of the radioactivity was 66 MBq (range 36-131 MBq). The tracer was 
administered at three or four sites around the tumor with a total volume of 0.3 ml to 0.4 
ml. Anterior dynamic lymphoscintigraphy was performed during 20 minutes immediately 
after injection. Images were obtained using a dual-head gamma camera (ADAC, Milpitas, 
CA, USA) with low energy high-resolution collimators. Subsequently, five-minutes 
anterior and lateral static images were obtained after 30 minutes and two hours post-
injection. A hot spot in the inguinal region was considered to be a sentinel node either if 
an afferent lymphatic channel was visualized, the hot spot was the only one in the basin, 
or the hot spot was the first one seen in a sequential pattern. The location of the sentinel 
node was marked on the skin using real time imaging and a 57Co-pen.  
Shortly before surgery, 1.0 ml patent blue dye (Blue Patenté V, Laboratoire Guerbet, 
Aulnay-sous-Bois, France) was intradermally injected around the tumor. The sentinel 
node was identified and harvested after dissection of blue lymphatic vessels and detection 
of radioactivity with a gamma ray detection probe (Neoprobe®, Johnson & Johnson 
Medical, Hamburg, Germany). Sentinel node biopsy was followed by local excision of the 
primary lesion or penile amputation during the same session. Sentinel nodes were 
bisected, formalin fixated, paraffin embedded and cut at six or more levels. Paraffin 
sections were stained with hematoxylin and eosin. Immunohistochemical staining was 
performed using pankeratin and CAM 5.2 (Becton Dickinson, San Jose, CA, USA). 
Primary tumors were staged according to the 1987 TNM system of the International 
Union Against Cancer and pathologically graded according to Broders as I: well 
differentiated, II: moderately differentiated, or III: poorly differentiated 8. Vascular 
invasion was defined as tumor cells within endothelium lined spaces. Routine 
confirmatory lymph node dissection was not performed. Standard inguinal lymph node 
dissection was reserved for groins with proven lymph node metastasis. Additional 
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ipsilateral pelvic (external iliac and obturator) lymph node dissection was performed if 
two or more inguinal lymph node were involved. The incision for sentinel 
lymphadenectomy was chosen in such a way that the biopsy scar could be included in the 
complete regional node dissection specimen. Sentinel node-negative patients were 
observed.  
 
Follow-up 
Patients were seen at two months intervals during the first two postoperative years, at 
three-months intervals in the third postoperative year and every 6 months thereafter. 
Median follow-up was 52 months (range 5-129 months). Two patients were lost to follow-
up because of emigration after 5 and 16 months. 
 
Statistical Analysis 
Chi-square test and Fisher’s exact test were used for univariate comparison. Disease-
specific survival plots were made using the Kaplan-Meier method and survival rates were 
analyzed for significance using the log rank test. Cox proportional hazards analysis was 
applied testing T-stage, tumor grade, vascular invasion, and sentinel node status for their 
independent effect on survival and recurrence. Individual model covariates were 
characterized with 95% confidence interval on the hazard ratio scale. Follow-up was 
measured from the date of sentinel node surgery. For disease-specific survival, the event 
was death as a result of penile cancer, and for disease-free survival, the event was nodal or 
distant recurrence. In the absence of an event, censoring took place at the last follow-up 
visit. Significance was determined at p<0.05. Analyses were performed with Statistical 
Package for the Social Sciences software (SPSS, Chicago, Illinois, USA).  
 
Results 
Lymphoscintigraphic visualization and surgical identification of the sentinel nodes 
Unilateral clinically node-negative patients: 13 of 17 unilateral clinically node-negative 
patients showed bilateral drainage and drainage to the unaffected side only was seen in the 
remaining four. At least one sentinel node could be identified during surgery in all 17 
explored basins. 
Bilateral clinically node-negative patients:  98 of 123 bilateral clinically node-negative 
patients showed bilateral drainage and unilateral drainage was observed in 23. No 
drainage at all was observed in the remaining two. At least one sentinel node could be 
identified during surgery in 226 explored basins. Exploration for sentinel nodes was not 
performed in 19 basins with lymphoscintigraphic non-visualization and not in one basin in 
which the radioactive count rate was not above the background count rate. 
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Altogether, 319 sentinel nodes were removed from 243 explored basins. One sentinel 
node was only palpable but neither blue-stained nor radioactive (0.3%), three (1%) were 
only blue, 95 (30%) were only radioactive, and 220 (69%) were both blue and radioactive. 
Pathology 
Unilateral clinically node-negative patients: 5 (29%) of 17 patients with a unilateral 
proven N1 stage had a positive sentinel node. 
Bilateral clinically node-negative patients:  26 (21%) of 123 bilateral clinically node-
negative patients had a positive sentinel node including six patients with bilateral sentinel 
node involvement.  
 
Altogether, the sentinel node was tumor-positive in 37 basins of 31 patients. 37 
complementary lymph node dissections were performed in the 31 sentinel node-positive 
patients. Pathologic examination revealed no further positive lymph nodes in 29 (78%) of 
these 37 lymphadenectomy specimens. In the remaining eight specimens, at least one 
additional positive lymph node was found. Primary tumor characteristics (i.e., T-stage (T2 
or T3), grade (I, II or III) and vascular invasion (absent or present)) and size of the 
sentinel node metastases (micro (≤2mm)- or macrometastases (>2mm)) were tested as 
possible prognostic factors for the presence of additional positive nodes. Only the size of 
the metastases in the sentinel node proved to be significantly related to the status of the 
additional lymph nodes (p=0.004). None of the groins with only a micrometastasis in the 
sentinel node (n=17) contained additional involved nodes.  
 
False-negative results and morbidity 
False-negative results, i.e. in field tumor outgrowth after excision of a classified tumor-
negative sentinel node or after non-visualization, occurred primarily at the beginning of 
the study and were encountered in six patients after a median interval of seven months 
(range 3-27). Five of these patients had bilateral clinically node negative groins and one 
had a unilateral node positive disease. In one of these false-negative cases, the groin was 
not explored because lymphoscintigraphy did not identify a sentinel node on this side. In 
another patient, lymphoscintigraphy showed only slight uptake and in hindsight it was to 
be concluded that the wrong node was taken out. Regional tumor recurrence was seen in 
four patients after tumor-free sentinel nodes had been harvested from the same groin. In 
one of these patients, additional serial sectioning and immunohistochemical staining of the 
sentinel node revealed metastasis after all. Four of these six patients died of disease and 
the other two are alive without evidence of disease. The false-negative rate, i.e. the 
number of false-negative results divided by the total of positive results plus the false-
negative results, is 16% (6 of 37) so far. Postoperative complications after sentinel node 
biopsy occurred in 8% (17 of 206) of the operated groins and were minor and transient, 
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including wound infection, wound abscess, skin edge necrosis, wound dehiscence and 
wound seroma. 
 
Disease-specific survival and disease-free survival  
Two patients in whom no sentinel node could be found and 17 patients with a unilateral 
N1 stage were excluded from survival analyses. Recurrence-free and overall survival of 
the patients with bilateral clinically node-negative groins were significantly associated 
with the result of the sentinel node biopsy. The estimated five-year disease-specific 
survival rates for patients with a tumor-negative or tumor-positive sentinel node were 96% 
and 66%, respectively (p = 0.001, Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1 
Disease-specific survival plot of
patients with a tumor-negative sentinel
node (SN-) or tumor-positive sentinel
node (SN+). Two patients in whom no
sentinel node could be found and 17
patients with a unilateral N1 stage were
excluded from survival analysis.
Numbers of patients at risk are
provided at each point of time (p =
0.001). 
The corresponding disease-free survival rates were 95% and 69%  (p = 0.001). In the 
sentinel node positive group all patients died of nodal recurrence with or without distant 
metastases. In the sentinel node negative group two patients died of nodal recurrences and 
one had a sarcomatoid squamous cell carcinoma and developed a distant metastases 
without evidence of lymph node metastases. Cox multiple regression analysis was 
performed with the following variables: T-stage (T2 or T3), pathological tumor grade (I or 
II + III), vascular invasion (absent or present), and sentinel node status (positive or 
negative). Only the status of the sentinel node proved to be a significant prognostic factor 
for both, disease-specific and disease-free survival (p = 0.01 (hazard ratio 6.8, 95% 
confidence interval 1.5-30.0) and p = 0.01 (hazard ratio 5.3, 95% confidence interval 1.4-
20.0), respectively).  
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Discussion 
Several benefits of sentinel node biopsy in penile carcinoma have become clear after 
having performed the procedure for more than 10 years at our institute. First of all, this 
minimally invasive operation decreases morbidity of staging by preventing unnecessary 
lymph node dissections. Contemporary series report complications after inguinal 
lymphadenectomy in up to 88%.9,10 Morbidity rate of sentinel node biopsy is 8% in the 
present series with all complications being minor and resolving without long-term 
sequelae.  
A second advantage of the sentinel node biopsy is improved staging. Instead of having to 
examine all the nodes of the regional basin, the pathologist can focus on one node or a few 
at the most: the node(s) most likely to contain metastases. This node can be scrutinized by 
means of techniques such as serial sectioning and immunohistochemistry. This study 
shows that the sentinel node status provides important prognostic information. Patients 
with a positive sentinel node had a poorer prognosis than those with a negative sentinel 
node with an absolute reduction in 5-year disease-specific survival and disease-free 
survival of 30% and 26%, respectively. In line with these results is our finding that the 
status of the sentinel node emerged as the only significant prognostic factor in 
multivariate analysis. Results in other tumor types are only suggestive for further research 
in penile carcinoma. Nevertheless, in patients with malignant melanoma and breast cancer 
the sentinel node status proved to be the most important prognostic factor as well and in 
these tumor types the sentinel node status has been incorporated in the TNM classification 
recently.11,12 Ongoing studies on sentinel node biopsy in penile carcinoma may result in 
similar adaptations of the TNM classification. 
A striking observation is that no additional positive lymph nodes were detected in the rest 
of the dissection specimen in 78% of patients with a positive sentinel node. In an attempt 
to characterize this subgroup, we compared the ones with and without additional positive 
lymph nodes in the dissection specimen. Although the numbers are small, the size of the 
metastases seems to predict the presence of additional positive lymph nodes. In other 
tumor types, efforts are also undertaken to predict non-sentinel node involvement. In 
breast cancer for instance it has been suggested that a combination of primary tumor size 
and size of the sentinel node metastasis is predictive for the chance of non-sentinel node 
involvement. Based on these criteria it has been proposed to abandon axillary clearance 
for patients with low risk of additional lymph node involvement.13 Progress in identifying 
patients with additional positive nodes is also made in malignant melanoma, for example 
by Lee et al. who found that thicker primary and larger sentinel node tumor size tumor 
size are factors that correlate with tumor-positive non-sentinel nodes.14 In addition, Starz 
et al. found a correlation between extent and morphology of the sentinel node metastasis 
and additional node involvement.15  
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Patients with unilateral node positive disease (N1) can be candidates for lymphatic 
mapping of the opposite side. In 12 of 17 such patients, the sentinel node on the 
contralateral side was tumor-negative and only unilateral inguinal lymphadenectomy was 
performed. One important caveat of the sentinel node procedure for penile carcinoma at 
our institute is the false-negative rate of 16%. Most false-negative cases were encountered 
early on during the study when the technique was not yet well established and the 
sensitivity of the procedure has increased over the last years. There might be two reasons 
for false-negative results: retrieval failure (the sentinel node was not found) and pathology 
failure (the sentinel node was excised but histological evaluation failed). More recently, 
important adaptations have been introduced in our sentinel node practice after analysis of 
the false-negative cases.16 To reduce retrieval failure, exploration of non-visualized basins 
should be considered for detection of blue stained lymph vessels and nodes. Intraoperative 
palpation of the explored area is mandatory to detect firm and enlarged lymph nodes that 
were not visualized due to tumor deposit blocking the ingress of tracers. Ultrasonography 
may help to identify such grossly involved lymph nodes preoperatively. Pathology failure 
will hopefully be avoided by extending the histological analysis of the sentinel node with 
serial sectioning and immunohistochemical staining. It is noteworthy that since these 
adaptations were made in 2001, 60 sentinel node procedures have been performed and no 
more false-negative results occurred. However, follow-up is still short and new false-
negative results may come to light. In an attempt to improve the accuracy of the procedure 
even further, carbon particles can be added to the tracers as an aid to direct the pathologist 
to the site in the sentinel node most likely to contain metastasis.17  
Over the last few years other investigators have published their initial experiences with 
dynamic sentinel node biopsy in penile carcinoma.18-21 The largest study to date was 
reported by Perdona et al.22 They performed sentinel node biopsy in 17 bilateral clinically 
node negative patients. Five patients had a positive sentinel node. In all patients 
subsequent lymph node dissection was carried out and all negative sentinel node biopsies 
were confirmed by tumor-negative dissection specimens.    
 
Conclusion 
Dynamic sentinel node biopsy in penile carcinoma is of important diagnostic, prognostic, 
and therapeutic value at the cost of only minor morbidity. The false-negative rate drops 
now that the procedure in our hands matures. In an attempt to further decrease morbidity, 
one should focus on finding prognostic factors for additional lymph node involvement and 
thus identify sentinel node positive patients in whom additional complementary dissection 
can be spared. 
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Introduction 
Penile carcinoma has a strong tendency for lymphatic dissemination. The inguinal lymph 
nodes are the first site of metastasis.1 Survival is related to the presence and extent of 
lymph node involvement.2 Most patients with penile carcinoma present without clinical 
evidence of nodal involvement, but approximately 25% of these patients harbor occult 
metastases in their groins. Imaging modalities to detect occult lymphatic spread are 
hampered by a low sensitivity and primary tumor characteristics as predictor for nodal 
disease are rather unreliable.3,4 As a consequence, elective bilateral inguinal lymph node 
dissection is generally performed. The disadvantage of this approach is that it is 
unnecessary in up to 80% of the patients because they do not have nodal disease. 
Moreover, inguinal lymphadenectomy is associated with considerable morbidity.5  
Minimal invasive dynamic sentinel node biopsy has emerged as an alternative for elective 
dissection in the management of clinically node-negative penile carcinoma.6 The sentinel 
node is defined as the node that receives lymphatic drainage directly from the primary 
tumor. The sentinel node is the first target of metastases and the source of further 
dissemination to downstream lymph nodes. A tumor-negative sentinel node predicts the 
absence of disease in the other nodes of the regional basin. A tumor-positive sentinel node 
raises the possibility of additional involved regional lymph nodes and indicates 
complementary inguinal lymphadenectomy. Several authors reported their experience 
with this promising minimally invasive technique.6-8  In our experience, the false-negative 
rate of this procedure is 16%.9 As is seen in most new surgical techniques most failures 
were encountered early on during the study, at the beginning of our learning curve. It is 
notable that the sensitivity of the procedure has increased over the last years. Hopefully in 
the near future the sensitivity will further increase to an acceptable >90%.   
An important observation is that the majority of the groins that were subjected to 
complementary lymph node dissection did not contain additional involved lymph nodes at 
our institute.9 Thus, most sentinel node-positive patients underwent an unnecessary 
complementary lymph node dissection in retrospect. This study was undertaken to identify 
factors predicting the presence of positive additional nodes so that other patients could be  
spared unnecessary inguinal node dissection. 
 
Patients and Methods 
Patients 
Between 1994 and 2004, 158 patients with a cT1-T3 squamous cell carcinoma of the 
penis underwent dynamic sentinel node biopsy at the Netherlands Cancer Institute. The 
study group consisted of 135 patients with bilateral clinically normal inguinal regions. In 
23 patients one groin was tumor-positive based on fine-needle aspiration cytology and 
they underwent dynamic sentinel node biopsy for the other groin. 
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Dynamic sentinel node biopsy and lymphadenectomy 
The day before surgery, lymphoscintigraphy was performed for lymphatic mapping. A 
gamma-ray detection probe and patent blue dye were used to identify sentinel nodes 
during surgery. Sentinel node biopsy was followed by treatment of the penile tumor 
during the same surgical session. Only patients with positive sentinel nodes underwent 
complementary inguinal lymph node dissection. Inguinal lymphadenectomy consisted of 
the removal of lymphatic tissue between the inguinal ligament cranially, the adductor 
longus muscle medially, the sartorius muscle laterally, the crossing point of the sartorius 
and adductor longus muscle caudally, and the pectineus muscle and the superficial 
femoral artery and vein dorsally. Additional ipsilateral pelvic (external iliac and obturator) 
lymph node dissection was performed if two or more inguinal lymph nodes were 
involved. 
 
Pathological examination 
Sentinel nodes were formalin fixed and, depending on the size, were sectioned at 3mm 
intervals and embedded in paraffin. Each paraffin block was cut at three levels with 150 
μm intervals. Paraffin sections were stained with hematoxylin and eosin. 
Immunohistochemical staining using pankeratin (Becton Dickinson, San Jose, California) 
was added to the histopathological assessment after the tenth patient and was used at one 
level. Non-sentinel nodes were routinely sectioned and stained with hematoxylin and 
eosin.   
The penile tumors were routinely examined and staged according to the 2002 TNM 
system of the International Union Against Cancer and graded according to Broders as 
well-differentiated, moderately differentiated, or poorly differentiated.10 Vascular invasion 
was defined as tumor cells within endothelium lined spaces. The tumor diameter was 
measured as the largest distance between two opposite tumor margins. 
All sentinel node-positive cases were reviewed for the purposes of this study. The size, i.e. 
the largest diameter, of each sentinel node metastasis was measured by the pathologist and 
classified as micrometastasis (defined as ≤2mm) or macrometastasis (defined as > 2mm) 
as formerly described in sentinel node biopsy in breast cancer.11 The complementary 
inguinal lymph node dissection specimens were retrieved and 415 non-sentinel nodes 
were re-examined for the presence of metastases with additional serial sectioning at three 
levels and staining with hematoxylin and eosin.   
 
Statistical analysis and follow-up 
Fisher’s exact test was used for univariate comparison. Logistic regression was applied to 
test pathological stage (pT1 or PT2-3), grade (G1 or G2-3), vascular invasion (absent or 
present), primary tumor diameter (< 2 cm or ≥2 cm ) and size of sentinel node metastases 
(macrometastasis or micrometastasis) for their independent effect on non-sentinel node 
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involvement in multivariate analysis. Patients were followed regularly at The Netherlands 
Cancer Institute with intervals of two months during the first two years after diagnosis, 
with intervals of three months in the third year and every six months thereafter. 
 
Results 
A tumor-positive sentinel node was found in 46 groins of 37 patients (nine patients had 
bilateral sentinel node involvement) and complementary lymph node dissections were 
carried out in these 46 cases. The mean number of sentinel nodes dissected per groin was 
1.5 (range 1-6). A total of 70 sentinel nodes were harvested of which 50 proved to be 
tumor-positive.  
Metastasis was initially found by routine histological evaluation in 17 out of 415 non-
sentinel nodes. Additional serial sectioning of the remaining 398 nodes revealed tumor in 
two more nodes, so that 19 of 415 non-sentinel nodes were found to contain metastasis in 
the end.  
The sentinel nodes were the only positive lymph nodes in 37 groins (80%), while non-
sentinel nodes were also tumor-positive in nine groins (20%). One non-sentinel node was 
tumor-positive in five groins, three non-sentinel nodes were tumor-positive in two groins 
and four in the remaining two groins.  
 
Size of sentinel node metastasis 
The mean size of sentinel node metastases encountered in 45 groins was 6.3 mm (range: 
0.4-26 mm). In one groin only isolated tumor cells were found in the sentinel nodes. The 
sentinel node contained micrometastasis in fifteen groins and macrometastasis in 31 
groins.   
 
Non-sentinel node involvement 
Characteristics of the primary tumors and the size of sentinel node metastases are listed in 
Table 1. The size of the sentinel node metastasis proved to be the only predictive factor 
for non-sentinel node involvement (p = 0.02). Groins with a micrometastasis in the 
sentinel node only did not have additional lymph node involvement. In multivariate 
analysis, the size of the sentinel node metastasis was the only independent prognostic 
variable for non-sentinel node involvement (p = 0.02) (pathological stage (p=0.24), grade 
(p=0.31), vascular invasion (p=0.64), primary tumor diameter (p=0.29)).  
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p-value  SN 
positive 
only 
 
SN and 
additional 
lymph nodes 
positive 
 
Number of groins 37 9  
cT-stage    
2 29 7 1.0 
3 8 2  
pT-stage   
 
 
1 6 1 0.43 
 2 26 8  
 3 5 0  
Tumor diameter     
<2cm 10 1  0.42 
 ≥2 27 8  Tumor grade   
 
 
 
I 12 4 0.79 
 
II 15 3  
 
III 10 2  
Vascular invasion   
 
 
Absent 29 7 
 
1.0 
Present 8 2  
Size of SN metastasis     
Micrometastasis 
(≤2mm) 
15 0  0.02 
 
Macrometastasis 
(>2mm) 
22 9   
 
Table 1 
Clinicopathological features 
of 46 sentinel node positive 
groins in 37 patients classified 
according the additional 
lymph node status.  
 
 
Discussion 
In this series, the sentinel nodes were the only involved nodes in 80% of the tumor-
positive groins. Groins with sentinel node micrometastasis only did not have non-sentinel 
node involvement. This finding confirms the concept of orderly progression of lymph 
node metastases with increasing risk of tumor spread from sentinel nodes to non-sentinel 
nodes with increasing tumor load.12  The prediction of non-sentinel node involvement in 
breast cancer and melanoma has been the subject of several studies. In breast cancer, it 
has been found that a combination of primary tumor size, size of the sentinel node 
metastasis, lymphangioinvasion and number of sentinel nodes is predictive for the chance 
of non-sentinel node involvement.13 Based on these criteria it has been proposed to 
abandon axillary clearance for patients with a low risk of additional lymph node 
involvement.14 Most studies looking at the size of metastases alone demonstrate non-
sentinel node involvement in 10-15% of the patients with micrometastasis in the sentinel 
node.15 In melanoma, thicker primaries and larger size of sentinel node metastases 
correlate with tumor-positive non-sentinel nodes.16  However, it was not possible to 
identify a subset of patients without non-sentinel node involvement. Starz et al 
recommended a so-called micromorphometric classification based on location and extent 
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of the metastatic growth towards the hilum but also this approach was not completely 
reliable.17,18 A microanatomic classification was proposed by Dewar et al.18 They noticed 
that even just a few tumor cells in the sentinel node were sometimes associated with 
metastasis in other nodes. Patients with only a sub-capsular metastasis in the sentinel node 
did not have tumor-positive non-sentinel nodes. The rationale behind this observation is 
that metastatic cells initially arrive in the sub-capsular sinuses through an afferent lymph 
vessel. Later, there is subcapsular spread of malignant cells in the marginal sinuses and 
into the adjacent cortical parenchyma. Finally, these cells infiltrate the deeper zones of the 
lymph node parenchyma. During this process the chance of spread to subsequent nodes 
increases. A similar microanatomic classification may be useful in prediction non-sentinel 
node involvement in penile carcinoma. Some limitations of this study should be 
mentioned. First of all, the number of cases studied is limited. Furthermore, non-sentinel 
nodes were not stained with immunohistochemical techniques as was done for most 
sentinel nodes. In theory, small metastatic deposits may thus have been missed in the non-
sentinel nodes, although the additional value of immunohistochemical staining in 
detecting microscopic disease in penile squamous cell carcinoma seems limited. In our 
series of 50 tumor-positive sentinel nodes, immunohistochemical staining revealed only 
three positive nodes that were not identified by hematoxylin and eosin staining. An 
argument against omitting inguinal lymphadenectomy in penile carcinoma in case of a 
micrometastasis in the sentinel node is that there is no adjuvant therapy available like for 
instance in breast cancer. In addition, lymph node metastasis in penile carcinoma should 
be removed as early as possible because survival is related to the extent of nodal 
involvement.19 Another point of concern is that in one of our false-negative cases, with 
tumor relapse in a negative mapped basin, a micrometastasis was found in the sentinel 
node after all.20 Although speculative, this may suggest that non-sentinel node 
involvement can occur even in the case of sentinel node micrometastasis. More data from 
other institutions is needed before a decision is made to abandon complementary lymph 
node dissection in case of a sentinel node micrometastasis. Until that time, complementary 
lymph node dissection should remain the standard of care following any tumor-positive 
sentinel node.   
Conclusions 
The risk of non-sentinel node involvement in penile carcinoma patients is correlated with 
the size of the sentinel node metastasis. Groins with micrometastasis in the sentinel node 
only did not have additional metastasis in the rest of the inguinal lymph nodes. This 
suggests that these patients can be spared a complementary lymph node dissection. More 
studies with identical outcome are needed before such a regimen can be instituted. Until 
that time, complementary lymph node dissection should remain the standard of care in 
penile carcinoma patients with a tumor-positive sentinel node.  
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Future prospects  
Imaging alternatives for dynamic sentinel node biopsy  
Computerized tomography and magnetic resonance imaging have a low sensitivity and 
specificity in the detection of occult lymph node metastases.1-3 Ultrasound with fine-
needle aspiration cytology is more accurate.  However, as a staging tool it is inadequate 
with a sensitivity and specificity of 39% and 100% respectively, as reported in this thesis. 
The main problem is the detection of small metastases, i.e. smaller than approximately 3 
mm.  
Positron emission tomography with 18F-fluorodeoxyglucose (FDG-PET) has been 
advocated to detect occult lymph node metastases in several types of cancer. There is one 
case report on FDG-PET in penile carcinoma.4 This technique relies not solely on 
anatomic identification but largely on physiological characterization of cells. The majority 
of tumor cells have a higher glucose metabolism than normal cells. The glucose analogue 
deoxyglucose is preferentially taken up by tumor cells and, tagged with the radioactive 
isotope fluorine-18, it can be used to make functional images. However, the visualization 
by FDG-PET requires a minimum diameter of about 3 mm and this technique is therefore 
not a good alternative for dynamic sentinel node biopsy in staging patients with clinically 
node negative penile carcinoma.5  
As already pointed out in this thesis, magnetic resonance lymphangiography is a 
promising technique in the detection of occult lymph node metastases. This novel 
technique makes use of a lymph node specific contrast agent that allows the identification 
of clinically occult metastasis. This contrast agent, known as ultra small particles of iron 
oxide (USPIO), is injected intravenously and is taken up primarily by macrophages in the 
lymph nodes. Presence of USPIO in the node results in signal intensity loss (darkening) 
on T2-weighed sequences. Metastatic growth will displace the macrophages filled with 
USPIO which results in the metastatic part of the node being high in signal intensity 
(whitening). Thus, a metastasis in the lymph node will show as white filling defect. 
Metastases as small as 1mm have been detected by using this technique.6 In a mouse 
model even as few as 1,000 tumor cells could be depicted.7 Preliminary results of this 
technique in penile carcinoma are promising.8 Improvement of this technique could 
possible replace dynamic sentinel node biopsy in the future. 
 
Microarray 
New molecular technological advances can possibly help in unraveling the biologic 
behavior of neoplastic diseases. These new developments provide important prognostic 
information and may be helpful in detecting patients with a high risk of occult lymph node 
metastases. Genome wide profiling may make it possible to determine the biology of the 
disease based on the primary lesion. The recently developed DNA microarray gene 
expression might fulfill this promise. Preliminary experience with this technique in head 
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and neck squamous cell carcinoma has shown to be promising and maybe, in near future, 
occult metastases from penile carcinoma will be identified by means of this technique as 
well.9  
 
Concluding remarks 
Minimal invasive dynamic sentinel node biopsy is an important tool in staging clinically 
node-negative penile carcinoma. This technique identifies groins harboring occult 
metastases. Only these groins need to undergo complementary lymph node dissection, 
thereby preventing substantial overtreatment and the accompanying high morbidity that is 
encountered when elective lymph node dissection is performed in all clinically negative 
groins. The introduction of dynamic sentinel node biopsy, therefore, is an important 
advance in the surgical management of penile carcinoma. However, the exact role of this 
technique in the management of penile carcinoma can only be assessed after the procedure 
has disseminated to more institutions and the experience of other investigators has been 
published.  
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Summary  
Penile carcinoma primarily metastasizes to the inguinal lymph nodes. Even in case of  
lymphatic metastasis many patients can still be cured. Most penile carcinoma patients 
have no suspicious lymph nodes in their groins but this observation does not exclude the 
presence of  disease. Approximately 25% of the patients harbor occult metastases in these 
lymph nodes. An important issue in the management of penile carcinoma patients is how 
to identify these metastases. Elective lymph node dissection is an option but will lead to 
overtreatment in about 75% of the patients. Moreover, inguinal lymphadenectomy is 
associated with major morbidity. On the other hand, a wait-and-see policy may have a 
negative impact on survival. Dynamic sentinel node biopsy is a minimally invasive 
procedure that enables detection of occult metastasis in clinically node-negative groins. 
This technique was introduced for penile carcinoma at The Netherlands Cancer Institute - 
Antoni van Leeuwenhoek hospital in 1994. The aim of this thesis is to evaluate various 
aspects of dynamic sentinel node biopsy in patients with penile carcinoma.  
Chapter 1 contains a brief introduction on penile carcinoma and describes the outline of 
this thesis.  
In chapter 2, a review on penile carcinoma is provided focusing on the management of 
patients with clinically tumor-free regional lymph nodes.  
The indication for dynamic sentinel node biopsy is discussed in chapter 3. Stage and 
malignancy grade of the primary tumor are important predictive factors for the presence 
of occult lymph node metastases. By combining these two histopathologic characteristics, 
one can estimate the risk of nodal spread in patients with a T1-2 /G1-3 primary. This risk 
ranges from 7% to 45%. Relying solely on these characteristics for the decision to 
perform regional node dissection leads to unacceptable false-negative and false-positive 
rates. Only patients with a T1G1 primary tumor have a relatively low risk of occult lymph 
node metastases. Patients with these tumors may be good candidates for a surveillance 
policy. For all other patients, immediate histological assessment of the regional nodes is 
necessary. We suggest dynamic sentinel node biopsy for this purpose.   
In chapter 4, the clinical outcome of early versus delayed excision of lymph node 
metastases in penile carcinoma patients is investigated. This concerns one of the most 
controversial issues in the management of this disease. Forty patients with proven lymph 
node metastases were retrospectively included in this study. All patients presented initially 
with bilateral impalpable lymph nodes. In twenty patients, the metastases were removed at 
the time of clinical appearance during meticulous follow-up. The other twenty patients 
underwent early resection of their inguinal metastases detected by dynamic sentinel node 
biopsy before they became palpable. Disease-specific three-year survival of patients with 
positive lymph nodes detected during surveillance was 35% and in early resected cases 
this was 84% ( p<0.01). Thus, early resection of lymph node metastases improves disease-
specific survival. 
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The morbidity of dynamic sentinel lymph node biopsy compared to inguinal lymph node 
dissection in penile carcinoma is reported in chapter 5. Complications following dynamic 
sentinel node biopsy occurred in 7% of the groins, whereas after inguinal lymph node 
dissection this was 68% (p<0.001). All complications of dynamic sentinel node biopsy 
were minor and easily managed. Thus the conclusion is that the dynamic sentinel node 
biopsy is associated with a limited morbidity.  
A case of an unusual sentinel node localization is described in chapter 6. On the 
preoperative lymphoscintigraphy images, a prepubic sentinel node was depicted. This 
node could be surgically identified and proved to be tumor-positive. This case illustrates 
one of the advantages of dynamic sentinel node biopsy in penile carcinoma: 
lymphoscintigraphy can identify lymph nodes outside the usual nodal basins.  
The six false-negative dynamic sentinel node cases that were encountered in our study 
population are analyzed in chapter 7. In one of these, one groin was not explored because 
lymphoscintigraphy did not identify a sentinel node there. Non-visualization of the 
sentinel node may have been caused by massive tumor involvement  blocking the 
lymphatic inflow. In a second patient, additional serial sectioning and 
immunohistochemical staining of a sentinel node that was initially reported to be disease-
free revealed metastasis after all. In three patients, lymphatic inflow blockage and 
rerouting of lymph flow due to gross tumor involvement of the sentinel node were 
possibly the causes of the failure. The true sentinel node in this situation is bypassed and 
the tracers are diverted to another node that is falsely labeled as the sentinel node. In the 
sixth patient with a false negative result, a sentinel node that was visualized on the 
scintigram could not be retrieved during surgery because of the low radioactivity content 
in this node. 
Based on these failures, adaptations have been made in our indications for sentinel node 
biopsy and in our technique. In case of unilateral drainage on the lymphoscintigram, 
exploration of the non-visualized groin is advised. Exploration after injection of the blue 
dye can still reveal a blue vessel leading to a non-blue, non-radioactive sentinel node. 
Intra-operative palpation of the groin was introduced to detect suspicious nodes that could 
not be palpated through the skin. High-resolution ultrasonography with fine-needle 
aspiration cytology has been added as a routine examination before patients are scheduled 
for dynamic sentinel node biopsy. False-negative cases caused by gross involvement of 
the sentinel node with tumor blocking will hopefully be avoided by this approach because 
these are the very nodes picked up by the ultrasound. We also modified the routine 
pathological analysis because of the pathological sampling error. Sentinel nodes are now 
serially sectioned and immunohistochemistry is used in addition to standard hematoxylin 
and eosin staining.  
A varying lymphatic drainage pattern could also be a cause of a false-negative dynamic 
sentinel node procedure and this is studied in chapter 8. The reproducibility of 
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lymphoscintigraphy in the assessment of the location and the number of sentinel nodes 
was prospectively determined in twenty patients. Lymphoscintigraphy was performed 
twice in an identical fashion with a mean time interval of 21 hours. At least one sentinel 
node was visualized in all patients on the first lymphoscintigram. A total of 56 sentinel 
nodes were seen in 38 basins. The second lymphoscintigram revealed the same drainage 
pattern in all patients: the same number of sentinel nodes was visualized at identical 
locations. All sentinel nodes that were visualized on the first lymphoscintigram showed an 
unequivocal increase in radioactivity after repeat injection of the radioactive tracer. The 
reproducibility of penile lymphoscintigraphy was 100% (95% CI: 85-100%). Intra-
individual variability in lymphatic drainage is thus an unlikely explanation for false-
negative results of dynamic sentinel node procedures.  
In chapter 9 the accuracy of preoperative high-resolution ultrasonography-guided fine-
needle aspiration cytology is evaluated. Sensitivity and specificity of ultrasound-guided 
fine-needle aspiration cytology were 39% and 100% respectively. The quantity of groins 
on which a dynamic sentinel node procedure was performed was reduced by 11%. The 
sensitivity of 39% demonstrates that ultrasound guided fine-needle aspiration cytology 
cannot replace dynamic sentinel node biopsy. However, this technique proved to be a 
useful tool for preoperative screening of the clinically node-negative groins. By detecting 
occult metastases, patients can immediately be scheduled for complete inguinal 
lymphadenectomy, avoiding unnecessary staging surgery.  
In chapter 10, the incidence and causes of non-visualization of sentinel lymph nodes on 
the preoperative lymphoscintigram are analyzed as well as the implications for further 
management. Preoperative lymphoscintigraphy visualizes a sentinel node in 89% of the 
groins. Visualization depends on the administered tracer dose. Unilateral drainage was 
initially interpreted as a normal physiological phenomenon and non-visualized groins 
were not explored. After the occurrence of a tumor recurrence in a non-visualized groin, 
such groins are now explored using blue dye mapping and intraoperative palpation. 
Sentinel nodes were retrieved in four out of eight such groins of which one contained 
metastasis.  
An evaluation of the overall results of the dynamic sentinel node procedure in 140 patients 
with a median follow-up of more than four years is presented in chapter 11. Dynamic 
sentinel node biopsy proved to be of important diagnostic and prognostic value. Sentinel 
node metastasis was found in 31 patients (22%). Five-year disease-specific survival was 
96% and 66% for patients with a tumor-negative sentinel node and tumor-positive sentinel 
node, respectively (p=0.001).  
In Chapter 12, predictive factors for additional (non-sentinel) node involvement are 
analyzed. Sentinel node metastasis was found in 46 inguinal regions in 37 patients and a 
complementary lymph node dissection was routinely carried out in these cases. The 
sentinel node was the only tumor-positive node in 39 of the 46 dissection specimens 
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(80%). In uni- and multivariate analysis, the size of the sentinel node metastasis proved to 
be the only significant prognostic variable for additional lymph node involvement (both p 
= 0.02). No additional lymph node involvement was found when a micrometastasis (≤ 
2mm) was present in the sentinel node. Maybe such patients can be spared a 
complementary inguinal lymph node dissection in the future. 
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Samenvatting 
Het peniscarcinoom metastaseert met name naar de lymfeklieren in de liezen. Ook nadat 
dit is opgetreden is nog een groot gedeelte van de patiënten te genezen. De meeste 
patiënten presenteren zich met liezen die klinisch onverdacht zijn maar dit wil niet zeggen 
dat er geen metastasen in aanwezig zijn. Ongeveer 25% van deze patiënten herbergt 
namelijk occulte metastasering in de liesklieren. Een belangrijke vraag is hoe deze 
metastasen te detecteren zodat ze behandeld kunnen worden. Electieve dubbelzijdige 
lymfeklierdissectie is een mogelijkheid die veel wordt toegepast, maar deze ingreep is 
zoals uit bovenstaande blijkt in ongeveer 75% van de gevallen onnodig. Bovendien gaat 
een liesklierdissectie met aanzienlijke morbiditeit gepaard. Aan de andere kant brengt een 
afwachtend beleid, waarbij alleen die patiënten worden geopereerd bij wie klieren 
palpabel worden tijdens de follow-up, mogelijk een kortere overleving met zich mee. De 
dynamische schildwachtklierprocedure is een minimaal invasieve procedure die het 
mogelijk maakt occulte metastasering aan te tonen in klinisch onverdachte liezen. Deze 
techniek werd, voor wat het peniscarcinoom betreft, in 1994 geïntroduceerd in het 
Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis. Het doel van dit 
proefschrift is om de toepassing van de dynamische schildwachtklierprocedure bij het 
peniscarcinoom te evalueren.  
 
In hoofdstuk 1 wordt een korte introductie gegeven over het peniscarcinoom. Daarnaast 
wordt de opbouw van dit proefschrift uiteengezet.  
Hoofdstuk 2 behelst een algemeen overzicht over het peniscarcinoom waarbij de nadruk 
ligt op de problematiek en behandeling van patiënten met klinisch onverdachte liezen.  
De indicatie voor een dynamische schildwachtklierprocedure wordt besproken in 
hoofdstuk 3. Het stadium en de gradering van de primaire tumor blijken belangrijke 
voorspellers voor occulte lymfogene metastasering. Wanneer deze twee 
histopathologische tumorkarakteristieken worden gecombineerd is het mogelijk om het 
risico op occulte metastasering in te  schatten. De kans daarop loopt uiteen van 7% tot 
45% voor patiënten met een T1-2/G1-3 tumor. Wanneer slechts vertrouwd wordt op deze 
tumorkarakteristieken zal het wel of niet uitvoeren van een liesklierdissectie derhalve 
leiden tot frequente foutnegatieve en foutpositieve uitkomsten. Alleen patiënten met een 
T1G1 tumor hebben een vrij lage kans op aanwezigheid van occulte metastasen in hun 
liezen. Patiënten met een dergelijke tumor lijken daarom goede kandidaten voor een 
afwachtend beleid. Voor de overige patiënten is echter histologisch onderzoek van de 
lymfeklieren noodzakelijk. Wij suggereren een dynamische schildwachtklierprocedure in 
deze gevallen.  
In hoofdstuk 4 wordt de overleving vergeleken van patiënten bij wie kliermetastasering in 
een vroeg - nog niet palpabel - stadium werd verwijderd en patiënten die een late resectie 
van de - inmiddels palpabel geworden - metastasen ondergingen. Het vraagstuk op welk 
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moment aangetaste inguïnale klieren verwijderd moeten worden is één van de meest 
controversiële kwesties bij de behandeling van het peniscarcinoom. Er werden 
retrospectief veertig patiënten met bewezen lymfekliermetastasering opgenomen in deze 
studie. Alle patiënten presenteerden zich aanvankelijk met bilaterale klinisch niet 
verdachte liezen. Bij twintig patiënten werden de metastasen verwijderd op het moment 
dat ze palpabel werden tijdens follow-up. De overige twintig patiënten ondergingen 
vroege resectie van hun niet palpabele metastasen door middel van een dynamische 
schildwachtklierprocedure gevolgd door aanvullende liesklierdissectie. De 
ziektespecifieke drie-jaarsoverleving van de patiënten bij wie de inmiddels palpabele 
metastasen tijdens de follow-up verwijderd werden bedroeg 35%. Dit percentage was 84 
voor de patiënten bij wie na een dynamische schildwachtklierprocedure de  metastasen 
vroeg verwijderd werden (p<0.01). Het vroeg verwijderen van lymfkliermetastasen 
verbetert dus de ziektevrije overleving.  
De morbiditeit van de dynamische schildwachtklierprocedure in vergelijking met die van 
een liesklierdissectie wordt in hoofdstuk 5 besproken. Complicaties na een dynamische 
schildwachtklierprocedure werden in 7% van de gevallen waargenomen. Na een 
liesklierdissectie was dit percentage 68% (p<0.001). De complicaties van de dynamische 
schildwachtklierprocedure waren alle gering en konden eenvoudig verholpen worden. De 
morbiditeit van de dynamische schildwachtklierprocedure is dus laag.  
Een casus van een ongewone schildwachtklierlokalisatie wordt beschreven in hoofdstuk 
6. Het preoperatieve lymfoscintigram toonde een prepubisch gelokaliseerde 
schildwachtklier. Deze klier kon chirurgisch worden verwijderd en bleek een metastase te 
bevatten. Deze casus illustreert nog een voordeel van dynamische 
schildwachtklierbiopsie, namelijk dat lymfeklieren kunnen worden geïdentificeerd die 
zich buiten het gebruikelijke lymfeklierstation bevinden.  
De zes foutnegatieve dynamische schildwachtklierprocedures in onze studiepopulatie 
worden in hoofdstuk 7 geanalyseerd. Bij één van deze gevallen werd een lies niet 
geëxploreerd omdat lymfoscintigrafie in deze lies geen schildwachtklier toonde. Een 
mogelijke verklaring hiervoor is dat de schildwachtklier voor een groot deel was 
ingenomen door tumor waardoor blokkade van de lymfestroom ontstond met een 
foutnegatieve uitkomst als gevolg. Bij een andere patiënt bleek de als normaal afgegeven 
schildwachtklier toch metastasen te bevatten nadat deze later op serie was gesneden en 
immunohistochemisch was onderzocht. Blokkade door een relatief grote hoeveelheid 
tumor in de schildwachtklier met als gevolg daarvan een veranderde lymfestroom was 
mogelijk de oorzaak bij drie andere foutnegatieve procedures. De echte schildwachtklier 
wordt in deze situatie niet gedetecteerd en de speurstoffen worden naar een andere klier 
geleid die vervolgens als schildwachtklier wordt aangemerkt. Bij de laatste patiënt met 
een foutnegatieve uitkomst bleek dat een op het lymfoscintigram wel gevisualiseerde 
schildwachtklier tijdens de operatie niet kon worden geïdentificeerd als gevolg van een te 
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geringe hoeveelheid radioactiviteit van deze klier. Gebaseerd op deze foutnegatieve 
procedures zijn veranderingen aangebracht in ons schildwachtklierprotocol. Wanneer 
sprake is van unilaterale drainage op het lymfoscintigram wordt de niet gevisualiseerde 
lies toch geëxploreerd. Na injectie van patent blauw kan dan wellicht een blauw lymfevat 
worden gevonden dat naar een niet blauwe, niet radioactieve schildwachtklier leidt. Ook is 
palpatie van de operatiewond geïntroduceerd. Hierdoor kunnen peroperatief verdachte 
klieren gevoeld worden die niet goed preoperatief door de intacte huid beoordeeld konden 
worden. Daarnaast is de pathologisch bewerking van de schildwachtklier aangepast. 
Schildwachtklieren worden nu op serie gesneden en immunohistochemische kleuring is 
aan de kleuring met hematoxyline en eosine toegevoegd. Tenslotte is hogeresolutie-
echografie met dunnenaaldaspiratiecytologie geïntroduceerd als een routineonderzoek 
voordat patiënten een dynamische schildwachtklierbiopsie ondergaan. Hopelijk kunnen zo 
foutnegatieve gevallen als gevolg van blokkade van de lymfestroom door een relatief 
grote hoeveelheid tumor in de schildwachtklier worden vermeden. Juist deze klieren 
kunnen namelijk door de echo gedetecteerd worden.  
Variabiliteit in het drainagepatroon van de lymfe kan in principe de oorzaak zijn van een 
foutnegatieve dynamische schildwachtklierprocedure. Om het inzicht hierin te vergroten 
wordt in hoofdstuk 8 de reproduceerbaarheid van de lymfoscintigrafie onderzocht. 
Twintig patiënten werden prospectief in deze studie opgenomen. Lymfoscintigrafie werd 
tweemaal op identieke wijze uitgevoerd met een gemiddeld interval van 21 uur. Bij alle 
patiënten werd op de eerste scintigrammen tenminste één schildwachtklier gevisualiseerd. 
In totaal werden 56 schildwachtklieren gezien in 38 lymfeklierstations. Het tweede 
lymfoscintigram toonde eenzelfde drainagepatroon bij alle patiënten. Hetzelfde aantal 
schildwachtklieren werd gevisualiseerd op identieke locaties. Bovendien werd in elke 
schildwachtklier toename van radioactiviteit waargenomen na de tweede injectie met de 
radioactieve speurstof. De reproduceerbaarheid van de lymfoscintigrafie was dus 100% 
(95% BI: 85-100%). Intra-individuele variabiliteit van lymfedrainage is daarom 
onwaarschijnlijk als verklaring voor foutnegatieve dynamische 
schildwachtklierprocedures.  
In hoofdstuk 9 wordt de betrouwbaarheid van preoperatieve hogeresolutie-echografie met 
geleide dunnenaaldaspiratiecytologie onderzocht. De sensitiviteit en specificiteit van deze 
techniek bedroegen respectievelijk 39% en 100%. De schildwachtklierprocedure kon 
achterwege gelaten worden bij 11% van de liezen. De sensitiviteit van 39% houdt in dat 
de combinatie van echo en dunnenaaldaspiratiecytologie de schildwachtklierprocedure 
niet kan vervangen. Echter, echo en dunnenaaldaspiratiecytologie is wel nuttig om de 
klinisch kliernegatieve liezen preoperatief te screenen. Wanneer occulte metastasen op 
deze manier ontdekt worden kunnen patiënten direct een liesklierdissectie ondergaan en 
kan onnodige stadiërende chirurgie worden voorkomen.  
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In hoofdstuk 10 worden de incidentie en oorzaak van nonvisualisatie van 
schildwachtklieren op het preoperatieve lymfoscintigram onderzocht. Bovendien worden 
de gevolgen van nonvisualisatie voor het verdere beleid geanalyseerd. Preoperatieve 
lymfoscintigrafie visualiseerde een schildwachtklier in 89% van de liezen. De intensiteit 
van de visualisatie bleek af te hangen van de toegediende dosis radioactieve speurstof. 
Unilaterale drainage werd aanvankelijk geïnterpreteerd als een normaal fysiologisch 
verschijnsel en daarom werden liezen waarin geen schildwachtklier werd gedetecteerd 
niet geëxploreerd.In een van deze niet-geëxploreerde liezen kwam tijdens follow-up 
echter een tumorpositieve klier aan het licht. Sindsdien wordt bij non-visualisatie ter 
plaatse geëxploreerd, waarbij met behulp van patent blauw en intraoperatieve palpatie 
gezocht wordt naar de schildwachtklier. Op deze wijze werden in vier van de acht liezen 
waarbij geen radioactiviteit werd gezien op het lymfoscintigram toch een schildwachtklier 
gevonden. Eén van deze vier schildwachtklieren bevatte een metastase.  
In hoofdstuk 11 worden de resultaten gepresenteerd van tien jaar dynamische 
schildwachtklierprocedure bij 140 patiënten met een mediane follow-up van meer dan vier 
jaar. De dynamische schildwachtklierbiopsie bleek van belangrijke diagnostische en 
prognostische waarde. Schildwachtkliermetastasering werd gevonden bij 31 patiënten 
(22%). De vijf-jaars-ziektevrije overleving was 96% voor patiënten met een 
tumornegatieve schildwachtklier en 66% voor patiënten met een tumorpositieve 
schildwachtklier (p=0.001).  
In hoofdstuk 12 worden voorspellende factoren voor metastasering in andere dan de 
schildwachtklieren onderzocht. In 46 liezen van 37 patiënten bleek de schildwachtklier 
tumorpositief en werd een aanvullende klierdissectie uitgevoerd. De schildwachtklier 
bleek de enige tumorpositieve klier in 80% van deze gevallen. In liezen waarbij de 
schildwachtklier slechts een micrometastase (≤ 2mm) bevatte waren de overige klieren 
alle negatief. Wellicht dat in de toekomst geen aanvullende liesklierdissectie hoeft te 
worden verricht in deze gevallen. 
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Appendix   
Het plaveiselcelcarcinoom van de penis komt niet vaak voor. Metastasering vindt met 
name plaats naar de lymfeklieren in de liezen. Hematogene metastasering is zeldzaam en 
treedt vrijwel alleen op na uitgebreide lymfekliermetastasering. De standaardbehandeling 
bestond tot voor kort uit amputatie van de penis en dubbelzijdige lies- en 
bekkenklierdissectie. De afgelopen vijftien jaar is de behandeling van het peniscarcinoom 
veranderd.1 Het gevolg hiervan is dat tegenwoordig veelal minder mutilerend kan worden 
opgetreden zonder dat daarbij concessies worden gedaan aan het uiteindelijke 
oncologische resultaat. In deze casuïstische mededeling willen wij deze veranderde, meer 
toegesneden, hedendaagse behandeling illustreren aan de hand van vier casus. 
 
Ziektegeschiedenissen 
Patiënt A, een 60 jarige man, werd verwezen in verband met een afwijking aan de penis 
die hij enige weken eerder had opgemerkt. Bij lichamelijk onderzoek was op de glans een 
afwijking zichtbaar met een diameter van 1,5 cm (Figuur 1). In de liezen werden geen 
verdachte lymfeklieren gevoeld. Er werd een incisiebiopsie van de afwijking aan de penis 
uitgevoerd. Pathologisch onderzoek toonde een goed gedifferentieerd 
plaveiselcelcarcinoom dat invasief groeide tot in het subepitheliale weefsel. De tumor 
werd geclassificeerd als cT1N0M0 (TNM classificatie peniscarcinoom, Tabel 1).  
 
Tabel 1 
TNM-classificatie voor het peniscarcinoom (UICC, 2002)  
T Primaire tumor 
X Primaire tumor niet onderzocht 
0 Geen aanwijzingen voor een primaire tumor 
is Carcinoom in situ 
a Niet -invasief verruceus carcinoom 
1 Tumor invadeert subepitheliale weefsel 
2 Tumor invadeert corpus spongiosum of corpus cavernosum 
3 Tumor invadeert urethra of prostaat 
4 Tumor invadeert andere aangrenzende structuren  
  
N Regionale  lymfeklieren  
X Regionale lymfekliermetastasering niet onderzocht 
0 Geen aanwijzingen voor regionale lymfekliermetastasering 
1 Metastasering in één liesklier  
2 Metastasering in meerder liesklieren  
3 Metastasering in bekkenklieren, uni- of bilateraal 
  
M Metastasering op afstand 
X Metastasering op afstand niet onderzocht 
0 Geen aanwijzingen voor metastasering op afstand 
1 Metastasering op afstand 
 
Besloten werd om een penissparende behandeling uit te voeren met behulp van de Nd:Yag 
laser. Na chirurgische excisie met krappe marges werd het wondbed met behulp van de 
laser behandeld. Het defect werd niet gesloten. De patiënt kon diezelfde dag nog naar 
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huis. Pathologisch onderzoek van de primaire tumor bevestigde de diagnose (pT1NXMX). 
Acht weken later was de wond genezen. Vier jaar later zijn er geen aanwijzingen voor 
locoregionaal recidief. Het cosmetische en functionele resultaat is uitstekend (Figuur 1).  
Figuur 1 
Patiënt A. Oppervlakkig peniscarcinoom voor en na laserbehandeling. 
Afbeelding 1: Voor behandeling. 
Afbeelding 2: Vier weken na behandeling.  
Afbeelding 3: Eén jaar na behandeling.  
 
 
 
 
 
 
 
 
 
 
 
 
1 2 3
 
Patiënt B, een 52 jarige man, presenteerde zich elders in verband met  een zwelling aan de 
penis. De zwelling bestond reeds zes maanden en nam langzaam in omvang toe. Een 
incisiebiopsie toonde goed gedifferentieerd plaveiselcarcinoom met doorgroei in het 
corpus spongiosum. Patiënt werd verwezen voor behandeling. Bij lichamelijk onderzoek 
werd een 2,5 cm groot proces op de glans van de penis waargenomen. In geen van beide 
liezen werden afwijkende klieren gepalpeerd. Ook echografisch onderzoek van de liezen 
was zonder bijzonderheden. De tumor werd geclassificeerd als cT2N0M0. Besloten werd 
tot amputatie van de glans en een schildwachtklierprocedure. Op het lymfoscintigram 
werden in de linkerlies twee schildwachtklieren en in rechterlies één schildwachtklier 
gevisualiseerd (Figuur 2).  
 
Figuur 2 
Lymfoscintigram van patiënt B. Vanaf
de inspuitplaats van de radioactieve
stof rondom de tumor zijn lymfebanen
zichtbaar die draineren naar de
schildwachtklieren in beide liezen
(links één, rechts twee). 
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De volgende dag werden de drie radioactieve klieren met behulp van een 
gammastralendetectieprobe en blauwe speurstof geïdentificeerd en vervolgens 
geëxcideerd. Hierna werd de glans gereseceerd en werd de urethra in het uiteinde van de 
penisstomp gehecht. Het postoperatieve beloop was ongecompliceerd en drie dagen later 
kon patiënt worden ontslagen. Pathologisch onderzoek van de primaire tumor bevestigde 
de diagnose. Geen van de schildwachtklieren bleek uitzaaiingen te bevatten (pT2N0Mx). 
Patiënt is drie jaar na de operatie in goede conditie, zonder aanwijzingen van 
tumorrecidief. 
 
Patiënt C, een 65 jarige man, had sinds één jaar een zwelling op de penis bemerkt die 
langzaam in grootte was toegenomen. Biopsie elders liet een matig gedifferentieerd 
plaveiselcelcarcinoom zien met doorgroei in het corpus spongiosum. Onderzoek van de 
penis toonde een 3 cm grote zwelling op de overgang van de penisschacht en glans. In de 
liezen werden geen verdachte klieren gepalpeerd. Bij echografisch onderzoek van de 
liezen werd in beide liezen één afwijkende klier gezien. Deze werden echogeleid met een 
dunne naald aangeprikt en geaspireerd. Pathologisch onderzoek toonde in beide aspiraten 
tumorcellen van een plaveiselcelcarcinoom (cT2N2MX). Besloten werd een subtotale 
penisamputatie en een dubbelzijdige liesklierdissectie te verrichten. De urethra werd in het 
uiteinde van de penisstomp gehecht. Het postoperatieve beloop werd gecompliceerd door 
beiderzijds abcedering van de lieswonden. Twaalf dagen later kon patiënt worden 
ontslagen. Pathologisch onderzoek van de primaire tumor bevestigde de diagnose. In de 
liesklierdissectiepreparaten links en rechts bleken respectievelijk één van de acht en één 
van de elf klieren tumorpositief  (pT2N2Mx). Op grond van deze bevindingen werd 
afgezien van aanvullende verwijdering van de bekkenklieren. Drie jaar na de operatie is 
patiënt in goede conditie zonder aanwijzingen voor tumorrecidief. Wel heeft hij veel last 
van lymfoedeem aan benen en scrotum. 
 
Patiënt D, een 73 jarige man, werd van elders verwezen in verband met een sinds 
anderhalf jaar bestaande zwelling aan de penis die de laatste maanden sterk in omvang 
was toegenomen. Een incisiebiopsie toonde invasief matig gedifferentieerd 
plaveiselcarcinoom met doorgroei in het corpus spongiosum. Bij lichamelijk onderzoek 
was een 6 cm grote zwelling rondom de basis van glans zichtbaar. In de linkerlies werd 
een afwijkende klier gepalpeerd. In de rechterlies werden geen verdachte klieren gevoeld. 
Cytologische punctie van de klier in de linkerlies toonde cellen van een 
plaveiselcelcarcinoom. Echografisch onderzoek van de rechterlies liet geen verdachte 
klieren zien. De tumor werd geclassificeerd als cT2N1M0. Besloten werd rechts een 
schildwachtklierprocedure te verrichten. Op het lymfoscintigram werden hierbij twee 
schildwachtklieren gezien, die tijdens de operatie konden worden geïdentificeerd en 
geëxcideerd. Vervolgens werd een liesklierdissectie links verricht. In verband met de 
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grootte van de tumor werd de penis geamputeerd en werd de urethra perineaal ingehecht. 
Het postoperatieve beloop werd gecompliceerd door wondrandnecrose en dehiscentie van 
de liesklierdissectiewond. Twee weken na de operatie kon patiënt ontslagen worden. 
Pathologisch onderzoek toonde een matig gedifferentieerd plaveiselcelcarcinoom met 
doorgroei tot in de urethra. Eén van de twee schildwachtklieren uit de rechter lies bevatte 
een metastase. In het liesklierdissectiepreparaat links waren drie van de elf klieren 
positief. Op grond van deze uitslagen werd een liesklierdissectie rechts en een 
aanvullende bekkenklierdissectie links uitgevoerd. Het postoperatieve beloop verliep nu 
ongecompliceerd en patiënt kon zes dagen later ontslagen worden. In het 
liesklierdissectiepreparaat werden geen positieve klieren meer gevonden (pT3N3MX). In 
het bekkenklierdissectiepreparaat was één van de acht klieren positief. Besloten werd 
patiënt te bestralen op linker lies en linker bekkenhelft en af te zien van een aanvullende 
bekkenklierdissectie rechts. Vier jaar later is hij vrij van tumor. Hij heeft lymfoedeem aan 
het scrotum en aan het linkerbeen, hetgeen hem behoorlijk invalideert.    
 
Beschouwing 
Het peniscarcinoom komt in Nederland ongeveer 80 keer per jaar voor. De incidentie 
ervan stijgt met de leeftijd. De gemiddelde leeftijd waarop patiënten zich presenteren met 
de ziekte is 60 jaar.2 Histologisch gaat het in 95% van de gevallen om 
plaveiselcelcarcinoom. De anatomische locatie is in meer dan 80% van de gevallen de 
glans.3 Phimosis en Humaan Papilloma Virus (HPV) infectie spelen een oorzakelijke 
rol.4,5  
 
Behandeling van de primaire tumor 
Amputatie van een deel of van de gehele penis is de traditionele behandeling. Sinds eind 
jaren 80 van de vorige eeuw is ervaring opgedaan met penissparende behandeling met 
behulp van de laser (Nd:Yag en/of CO2 laser).6,7 De tumor wordt hierbij allereerst 
chirurgisch krap verwijderd en de wondbodem wordt aanvullend behandeld met de laser. 
Hiermee kan na de krappe resectie een additionele marge van 0,5 cm worden bereikt. 
Voor kleine oppervlakkige tumoren (Tis, Ta en T1) is deze behandeling veilig gebleken. 
Behandeling met laser is dan ook inmiddels de therapie van keuze voor deze tumoren. De 
morbiditeit is gering en zoals bij patiënt A beschreven is zijn de cosmetische en 
functionele resultaten uitstekend. Ook eventuele recidieven kunnen opnieuw met laser 
worden behandeld. Voor grotere en dieper invasieve tumoren geldt partiële of totale 
penisamputatie als voorkeursbehadeling.6 De behandeling voor een peniscarcinoom hoeft 
niet het einde van een actief seksueel leven te betekenen. Orgasme en ejaculatie blijven 
mogelijk, ook na penisamputatie. 8
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Diagnostiek en behandeling van de lymfeklieren 
Bij patiënten met bewezen lymfekliermetastasering is lymfeklierdissectie de aangewezen 
behandeling. Deze ingreep is curatief bij ongeveer 80% van de patiënten met één of twee 
tumorpositieve klieren. Zelfs bij metastasering in het bekken kan door dissectie van de 
bekkenklieren nog éénderde van de patiënten genezen.9,10 Nog niet zo lang geleden werd 
daarom standaard een gecombineerde lies- en bekkenklierdissectie aanbevolen. Inmiddels 
is duidelijk geworden dat de kans op positieve bekkenklieren afhankelijk is van het aantal 
positieve liesklieren. Wanneer slechts één klier in de lies positief blijkt te zijn, is de kans 
op een positieve bekkenklier buitengewoon klein.11 Daarom wordt tegenwoordig eerst 
alleen een liesklierdissectie uitgevoerd. Een aanvullende bekkenklierdissectie zoals 
patiënt D onderging, blijft gereserveerd voor patiënten met twee of meer positieve 
liesklieren.  
De behandeling van patiënten met een peniscarcinoom zonder palpabele klieren (ongeveer 
75% van de gevallen) vormt een uitdaging. Bij hen blijkt namelijk in ongeveer 20% van 
de gevallen reeds occulte lymfogene metastasering aanwezig te zijn.12,13 Electieve 
dubbelzijdige lymfeklierdissectie wordt bij deze groep nog steeds vaak toegepast. In 
ongeveer 80% wordt dan echter een onnodige ingreep gedaan. Bovendien is er sprake van 
aanzienlijke morbiditeit in de vorm van wondgenezingsstoornissen en lymfoedeem,14,15 
zoals geïllustreerd wordt door patiënten C en D. Een andere aanpak is om na behandeling 
van de primaire tumor te wachten en alleen die patiënten te opereren bij wie klieren 
palpabel worden. Het nadeel hiervan is dat wachten met dissectie tot palpabele klieren zijn 
ontstaan een kortere overleving met zich mee brengt.16 Verschillende onderzoekers 
hebben dan ook getracht op basis van histologische kenmerken van de primaire tumor 
occulte lieskliermetastasering te voorspellen. De kans hierop neemt toe naarmate de 
primaire tumor dieper infiltreert en een slechtere differentiatiegraad heeft. Patiënten met 
een oppervlakkige laaggradige tumor hebben een verwaarloosbare kans op occulte 
lieskliermetastasering.17,18 Voor deze groep is een frequente follow-up met echografische 
controle van de liezen te rechtvaardigden. Voor de overige patiënten blijken primaire 
tumorkenmerken slechts in beperkte mate de aan- of afwezigheid van occulte 
metastasering te kunnen voorspellen. Wellicht dat in de toekomst de kans op occulte 
metastasering beter geschat kan worden met behulp van genetische profilering van primair 
tumorweefsel door middel van moleculair-biologische technieken.19  
Sinds de komst van de hoge resolutie-echoapparatuur in het vorige decennium is het 
mogelijk niet alleen de grootte van een lymfeklier te onderzoeken maar ook eventuele 
veranderingen van corticale en hilaire structuren ervan op te sporen.20 Deze treden op 
voordat een klier door tumorgroei in omvang toeneemt. Echogeleide dunne-naald 
aspiratiecytologie van de verdachte klier laat vervolgens zien of er sprake is van 
metastasering. Wanneer dit het geval is, zoals bij patiënt C, volgt liesklierdissectie. 
Echogeleide dunne-naald aspiratiecytologie is een eenvoudige methode en is een 
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uitstekend initieel onderzoek van de klinisch onverdachte lies. Metastasen kleiner dan 
circa 2 mm worden echter gemist door de beperkte spatiële resolutie van de echokop. De 
uitslag van dit onderzoek is derhalve alleen van waarde indien positief. Met behulp van de 
schildwachtklierprocedure kunnen daarentegen ook kleinere metastasen worden 
opgespoord.21 Bij deze minimaal invasieve methode worden slechts die klieren van het 
regionale lymfekliergebied verwijderd waarop de tumor rechtstreeks heeft gedraineerd. 
Voor het opsporen van de schildwachtklieren wordt gebruik gemaakt van pre-operatieve 
lymfoscintigrafie, waarna intraoperatief de radioactieve klier door middel van een 
gammastralendetector en een blauwe speurstof wordt opgezocht. Alleen patiënten met een 
tumor-positieve schildwachtklier ondergaan aanvullende klierdissectie. Inmiddels 
beschikken wij over een ruime ervaring met deze techniek. Sinds 1994 werd deze 
procedure in ons instituut bij 123 patiënten toegepast, waarbij in 28 gevallen occulte 
metastasering in de liesklieren kon worden opgespoord zoals bij patiënt D. Bij 95 
patiënten, waaronder patiënt B, kon op deze wijze dus een liesklierdissectie worden 
voorkomen.22 Bij patiënten met twee of meer inguïnale kliermetastasen (patiënt D), 
extracapsulaire groei, of bekkenkliermetastasen verhoogt adjuvante radiotherapie de 
regionale controle.11 Wanneer er sprake is van voortgeschreden regionale ziekte kan door 
middel van systemische chemotherapie bij ongeveer 30% van de patiënten een respons 
worden bereikt waarbij liesklierdissectie alsnog mogelijk kan worden.23 Dit is van belang 
daar een regionaal niet controleerbaar proces gepaard gaat met ernstig lijden en nagenoeg 
steeds de dood tot gevolg heeft.  
 
Conclusie 
In deze casuïstische mededeling is de problematiek en hedendaagse behandeling van het 
peniscarcinoom aan de orde gesteld. Peniscarcinoom is één van de weinige maligniteiten 
die aanvankelijk vrijwel uitsluitend lymfogeen metastaseert. De ziekte is uitstekend 
chirurgisch te behandelen. Zelfs in geval van kliermetastasering is curatie mogelijk. 
Uitgebreide chirurgie van de primaire tumor en de regionale lymfeklieren is echter 
mutilerend en slechts noodzakelijk bij een minderheid van de patiënten. In de laatste 
decennia is het mogelijk geworden patiënten met peniscarcinoom meer toegesneden te 
behandelen. De introductie van behandeling met de laser heeft het aantal penisamputaties 
bij patiënten met een lokaal weinig voortgeschreden tumor sterk doen verminderen. Bij de 
behandeling van de klinisch onverdachte regionale klieren lijken hogeresolutie echografie 
met dunne-naald aspiratiecytologie en de schildwachtklierbiopsie als stadiëring de plaats 
ingenomen te hebben van de met veel morbiditeit gepaard gaande electieve 
liesklierdissectie. Bij aangetaste lymfeklieren moet uiteraard wel steeds een 
liesklierdissectie volgen. Een aanvullende bekkenklierdissectie blijft gereserveerd voor 
patiënten met twee of meer positieve klieren.  
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